

# The Other Drug War II

## Drug Companies Use an Army of 623 Lobbyists to Keep Profits Up

### Executive Summary

This new Public Citizen report, the third in as many years, shows how the biggest drug companies and their trade associations employed more lobbyists and spent more on Washington, D.C. lobbying in 2001 than in previous years. This lobbying increase occurred while overall lobbying by all industries appeared to decline in 2001, based on available data.

The drug industry's lobbying money was well spent. Although the industry faced mounting pressure in 2001 from employers, politicians and senior citizens to make prescription drugs more affordable and accessible, drug companies lost no legislative battles last year. Instead, they actually gained ground – and additional profits – thanks to federal legislation that extends the lucrative monopoly patent protections for some drugs if they are tested for safety in children. The success of drug companies in Washington, D.C. last year owes much to the industry's phenomenal lobbying efforts.

The full bill for that massive buttonholing operation recently became public with the availability of all lobby disclosure reports for the year 2001. Using these lobbying reports, along with information about the lobbyists' "revolving door" connections, Public Citizen's new report shows the following:

- The 10 most active drug companies and industry groups spent 16 percent more on Washington, D.C. lobbying in 2001 than the previous year. They increased the number of lobbyists they employed by 30 percent. (See Table 1)
- The 10 most active drug companies and industry groups boosted lobbying expenditures from \$43 million in 2000 to \$49.8 million in 2001. The number of lobbyists they employed increased from 417 to 541. These top 10 companies and industry groups accounted for two-thirds of all drug industry lobbying expenditures in 2001.
- Overall, drug companies spent \$78.1 million on lobbying in 2001, bringing the total lobbying bill for 1997-2001 to \$403,071,467. (See Table 2) The companies employed 623 different individual lobbyists in 2001 – or more than one lobbyist for every member of Congress.
- 23 of those lobbyists are former members of Congress. (See Table 3) In 2000, 21 former members of Congress lobbied for the drug industry.
- 340 of those lobbyists (54 percent) have "revolving door" connections; in other words, they previously worked in Congress or another branch of the federal government. (See Table 4) In 2000, 316 lobbyists had revolving door connections.
- This army of lobbyists waged several successful campaigns. The issues they lobbied on most were: Medicare prescription drug benefit, patents, pediatric exclusivity, and prices. In each

area, the drug industry succeeded in 2001. Congress did not create a Medicare drug benefit; the industry's monopoly patent protections were not weakened; the pediatric incentive granting an extra six months of patent protection if a company tests the safety of its drugs in children was re-authorized (at a cost of \$14 billion to consumers); and consumer-friendly legislation giving U.S. consumers access to prescription drugs sold at significantly lower prices in foreign countries was not adopted.

- Overall, however, lobbying expenditures by the drug industry decreased in 2001, as the industry's total spending declined from \$92.3 million to \$78.1 million and the number of lobbyists dipped from 625 to 623. This was largely due to company mergers within the industry and dramatic reductions in spending by three companies – Schering-Plough (lobbying expenditures dropped \$6.3 million), Pharmacia (\$2.4 million decrease) and Abbott Laboratories (\$1.9 million dip).
- The biggest increase in lobbying activity was by the drug industry's trade association, Pharmaceutical Research and Manufacturers of America (PhRMA), which increased spending from \$7.5 million in 2000 to \$11.3 million last year (a 51 percent hike). PhRMA spent more on lobbying than any other drug industry organization in 2001.
- Other companies that significantly hiked their lobbying expenditures in 2001 were GlaxoSmithKline (28 percent jump), Eli Lilly (23 percent), Hoffman-LaRoche (23 percent), and Johnson & Johnson (17 percent).
- Four companies and PhRMA employed more than 50 different lobbyists in 2001. Pfizer and PhRMA employed the most (each hired 82 lobbyists), followed by Bristol-Myers Squibb (76 lobbyists). Eli Lilly and Amgen each fielded 58 lobbyists.
- In 2001, brand-name drug companies easily outgunned the generic drug companies they often compete with when it came to lobbying. Brand-name companies accounted for 97 percent of all pharmaceutical lobbying spending (\$75.7 million out of a \$78.1 million total). Brand-name companies also employed nine lobbyists for every one employed by generic companies.

## Introduction

Prescription drugs have become a hot topic in America's heartland and on Capitol Hill. National spending on prescriptions has soared, drug prices have climbed, and millions of elderly Americans have continued to pay for prescriptions out-of-pocket because they lack insurance that covers medicine. Meanwhile, the drug industry remained by far the most profitable industry in the U.S. In a year when overall profits of Fortune 500 companies fell 53 percent, the top 10 drug companies saw profits increase 33 percent from \$28 billion in 2000 to \$37.2 billion in 2001. (See Public Citizen's April 18, 2002 report, "Pharmaceuticals Rank As Most Profitable Industry, Again" at [http://www.citizen.org/documents/fortune500\\_2002erport.PDF](http://www.citizen.org/documents/fortune500_2002erport.PDF))

Yet despite this formula for outrage and action, Congress did nothing last year to make pharmaceuticals cheaper and more accessible for Americans.

How can this be? The answer is simple: It's a testament to the prowess of the drug industry's massive lobbying campaign.

Last year the industry fended off pro-consumer efforts on a number of fronts. In 2001, the drug industry thwarted congressional efforts to create a prescription drug benefit under Medicare with cost-containment provisions; it beat back a push to require drug manufacturers to sell their products to Medicare recipients at the same low prices they're sold at in other industrialized nations; and it held off attempts to make generic drugs more accessible.

Indeed, rather than giving any ground, the drug industry pushed Congress to pad the industry's bottom line with a multi-billion dollar incentive program that awards drug companies with an additional six months of monopoly patent protections. To gain these monopoly patent extensions, drug companies need only test some of their products in children.<sup>1</sup>

That particular effort was indicative of the way drug companies work in Washington, D.C. They employed dozens of well-connected lobbyists. (see "Patently Offensive," page 4) They issued ultimatums to members of Congress, saying that the legislation had to be exactly what the industry wanted or else children would suffer. And they built support for their position by funding a "grassroots" coalition – run by a former drug company lobbyist – that claimed to represent sick children.

Drug companies achieved this success and others thanks to an army of well-compensated lobbyists. The full bill for this lobbying assault recently became public with the availability of all lobby disclosure reports for the year 2001 (complete lobby disclosure reports typically lag four months behind the year's end).

The bottom line – which is detailed in this report – is once again sobering for health care advocates.

## Who Didn't Lobby for the Drug Industry?

Lobbying by all industries in Washington, D.C. appeared to dip last year because of an overall slump in the American economy.<sup>2</sup> But the biggest drug companies showed no signs of cutting back on their lobbying. Instead, they increased their lobbying expenditures and number of lobbyists in 2001.<sup>3</sup>

In fact, the 10 most active drug companies and industry groups spent 16 percent more on Washington, D.C. lobbying in 2001 than the previous year, as they boosted their lobbying bills from \$43 million to \$49.8 million. (See Table 1) These top 10 companies and industry groups accounted for two-thirds of all drug industry lobbying expenditure in 2001.

The biggest increase in lobbying activity was by the drug industry's trade association, Pharmaceutical Research and Manufacturers of America (PhRMA), which hiked spending 51 percent from \$7.5 million in 2000 to \$11.3 million last year. PhRMA spent more on lobbying than any other drug industry organization in 2001.

Other companies that significantly hiked their lobbying expenditures in 2001 were GlaxoSmithKline (28 percent jump), Eli Lilly (23 percent), Hoffman-LaRoche (23 percent), Johnson & Johnson (17 percent) and Amgen (15 percent).

The 10 most active companies and trade groups also increased the number of lobbyists they employed by 30 percent, as their lobbying ranks swelled from 417 to 541 paid advocates.

(Public Citizen defines the drug industry as brand name and generic pharmaceutical companies and their trade associations. Several large biotechnology companies and their trade association are included because they share similar agendas as the brand-name pharmaceutical companies on intellectual property, Medicare drug benefit and pricing issues.)

Overall, the industry employed 623 different lobbyists and spent \$78.1 million on lobbying in 2001. (See Table 2) Since 1997, the industry has spent \$403,071,467 to lobby the federal government. But the 2001 totals mark a decline from the previous year when drug companies and their trade associations employed 625 lobbyists and spent \$92.3 million.<sup>4</sup>

This industry-wide dip is largely due to dramatic reductions in spending by three companies: Schering-Plough (lobbying expenditures dropped \$6.3 million), Pharmacia (\$2.4 million decrease) and Abbott Laboratories (\$1.9 million dip).

In addition, mergers continue to play a part in consolidating the lobbying operations and expenditures of companies. For example, in 2000 Glaxo Wellcome spent \$3.13 million and SmithKline Beecham spent \$2.86 million on lobbying. But last year, the two companies merged into GlaxoSmithKline, and were able to eliminate some duplication in their lobbying efforts and reduce the number of lobbyists employed. As a result, the new GlaxoSmithKline spent \$4 million – or \$2 million less.

Furthermore, the drug industry faced less threatening political dynamics in 2001 than in the previous year. In 2000, a presidential election year, politicians were more focused on prescription drug issues than they had been in decades. And as part of election-year politics, members of Congress gave serious consideration to bills that aimed to provide comprehensive drug insurance through Medicare and control prescription prices. Thus, the industry felt more threatened in 2000 than in 2001, when the push for a Medicare benefit and mechanisms to contain drug costs abated.

That said, the drug industry – as defined by Public Citizen – still appeared to have spent more on lobbying in 2001 than any other industry, based on available data.<sup>5</sup>

### **Watch the Revolving Door**

In the process of employing 623 hired guns, the drug industry acquired the services of the top firms in Washington, D.C. and some of the best lobbyists.

For starters, the industry hired 23 former members of Congress. (See Table 3) These former members were almost evenly divided by party affiliation, with 13 Republicans and 10 Democrats shilling for the industry. They included Sens. Dennis DeConcini (D-Ariz.) and Steve Symms (R-Idaho), Reps. Vic Fazio (D-Calif.) and Bob Livingston (R-La.), and even the husband-wife team of former Reps. Susan Molinari (R-N.Y.) and Bill Paxon (R-N.Y.). In 2000, 21 former members of Congress lobbied for the drug industry.

The drug industry also made sure its operation was well-stocked with lobbyists who used to work in Congress or other branches of the federal government. In all, 340 drug industry lobbyists (54 percent of the total) came through the revolving door that spins between Capitol Hill and K Street. (See Table 4) In 2000, 316, or 50 percent of the 625 lobbyists, had revolving door connections.

These revolving door lobbyists include well-connected veterans, such as Haley Barbour, who was a top political adviser in the Reagan White House, as well as chairman of the Republican National Committee (RNC), where he raised money from pharmaceutical companies.<sup>6</sup> (Barbour is currently Finance Committee chairman of the National Republican Senatorial Committee.)

The industry added some impressive revolving door lobbyists to its roster last year. For example, Ronna Freiberg, who was legislative director for former Vice President Al Gore, lobbied for five drug industry clients in 2001. Steve Ricchetti, who was deputy chief of staff for ex-President Bill Clinton, had three drug industry clients last year. Wallace Henderson, who was chief of staff to Rep. W.J. “Billy” Tauzin (R-La.), chairman of the important House Energy and Commerce Committee, became a drug industry lobbyist last year; so did Cathy Abernathy, who was chief of staff for Rep. Bill Thomas (R-Calif.), the chairman of the House Ways and Means Committee.

## The Key Issues

Drug industry lobbyists worked on a variety of issues, ranging from tax credits to stem cell research. But above all they focused on legislative issues directly connected to the industry's financial bottom line. In 2001, that meant a Medicare prescription drug benefit, intellectual property protection, patent extensions, and prices.<sup>7</sup>

One can get a good sense of the industry's legislative priorities by examining the disclosure reports for the 10 most active companies and industry associations – and looking at the number of lobbyists they brought to bear on these issues.

Consider the issue of a Medicare prescription drug benefit. The 10 most active drug companies and industry groups employed 285 lobbyists who worked against a comprehensive prescription drug benefit administered by Medicare. The same 10 companies and groups employed 182 lobbyists who worked on patent and intellectual property protection issues. (Most lobbied against legislation, known as the Schumer-McCain bill, S. 812, which would make it easier for consumers to gain access to lower-cost generic drugs.)

Perhaps the best example of the drug industry's lobbying prowess was its work on a provision in federal law known by the mind-numbing name of "pediatric exclusivity." The provision amounts to a huge giveaway to the industry, in the form of a six-month monopoly patent extension. And with the help of industry lobbyists, pediatric exclusivity elbowed its way into Congress's busy post-September 11 agenda.

## Patently Offensive: A Case Study

The industry's goal was reauthorization of a law first passed in 1997 that gives a financial windfall to drug companies for testing the safety and efficacy of some pharmaceuticals in children. The government does not pay companies to test the safety of drugs in other population groups, such as women and minorities. It requires such tests. But drug companies had historically refused to test their products in children because the children's market for prescription drug is not as big and rewarding as the adult market.<sup>8</sup>

Anxious to get drugs tested in kids, Congress in 1997 resorted to a bribe, creating a financial incentive for pediatric tests – six months of added monopoly patent protection. Unfortunately, the pediatric incentive turned out to be too onerous to consumers and too generous to drug companies. Pediatric tests cost only \$3.9 million per drug on average,<sup>9</sup> while six-month patent extensions were worth more than \$1 billion in added sales for some blockbuster drugs.<sup>10</sup>

In January 2001, the federal Food and Drug Administration (FDA) estimated that the pediatric incentive would cost consumers \$14 billion in delayed access to cheaper generics over 20 years.<sup>11</sup> Rep. Henry Waxman (D-Calif.), the leading Democratic sponsor of the original patent extension legislation, wanted to revise the law so it dangled in front of drug companies something more like a carrot than a carat. "We don't have to pay this much," lamented Waxman. "In fact, if we paid this price in any other [policy] we'd call it waste, fraud and abuse."<sup>12</sup>

Waxman and other Democrats offered several amendments aimed at curtailing the drug industry's windfall from the pediatric patent extension.<sup>13</sup> (For example, one amendment would have replaced the six-month patent extension with a program to pay drug companies twice the costs of any pediatric studies.) But all of the amendments were defeated, thanks to Republicans, who voted almost unanimously against them, and some Democrats.<sup>14</sup> Why? In part, because when drug industry lobbyists got face time with members of Congress and staffers, their message was clear: "They were pretty pointed in saying, in effect, 'We'll walk away [if Congress trims the pediatric incentive]. We want our bill.'"<sup>15</sup>

That message was reinforced by children's health advocacy groups, such as the American Academy of Pediatricians (AAP), which felt it had no choice but to support the windfall incentive.<sup>16</sup> Together, lobbying by the industry and children's groups such as the AAP and the Coalition for Children's Health – which received funding from PhRMA and was headed by a former drug company lobbyist<sup>17</sup> – was potent. Children's advocates were "giving members of Congress who wanted to vote with PhRMA a fig leaf," said one key congressional staffer.<sup>18</sup>

The drug industry lobbied the House Energy and Commerce Committee, which had jurisdiction over the pediatric patent extension, in strategic fashion. Consider the efforts of Merck, the most successful drug company in America. To get the patent extension bill passed, Merck knew it needed to win friends among Democrats in the House Energy and Commerce Committee.

So Merck hired two former Democratic House staffers with close ties to the committee to lobby on the bill.<sup>19</sup> One was Kay Holcombe, who worked on the Energy and Commerce Committee, which had jurisdiction over the bill, from 1993 to 1997. The other was Stacey Rampy, a former health care aide to Rep. Anna Eshoo (D-Calif.). (PhRMA employed another former Energy and Commerce Committee staffer, Howard Cohen, who was committee counsel from 1988-1999, to lobby for the pediatric incentive.<sup>20</sup>) Suddenly, Rep. Eshoo emerged as the chief Democratic sponsor of the pediatric patent extension legislation.<sup>21</sup> Then, Eshoo led a group of committee Democrats who opposed all of the amendments aimed at curtailing the windfall incentive.

As the pediatric incentive bill moved out of the House committee of jurisdiction, the message was clear: opponents couldn't muster the votes to make the legislation more consumer-friendly. The dynamic was similar in the Senate. Drug companies made it clear that they had no intention to negotiate. "The message was always 'it's good for kids, it's good for innovation, don't screw with it or it could go away,'" said one Senate aide who was lobbied by the industry.<sup>22</sup>

And once again, drug companies employed lobbyists with key connections to Democrats such as Steve Ricchetti, who was deputy chief of staff for President Clinton and former executive director of the Democratic Senatorial Campaign Committee.<sup>23</sup> Ricchetti's firm (Ricchetti Inc.) lobbied for the pediatric bill on behalf of Eli Lilly and Pharmacia in 2001 and was paid \$390,000 from the two drug companies in that period.<sup>24</sup>

The pediatric incentive bill sailed through the full House and Senate and was signed into law.

## Most Popular Firms and Lobbyists

The drug industry was very good for Washington's "K Street" economy last year: 129 firms were paid to lobby for the industry, and 61 different lobbying firms earned at least \$100,000 from the drug industry in 2001.

The leading firm, in terms of income, was Powell, Goldstein, Frazer & Murphy, LLP, which specializes in patent law and intellectual property protection. Its earnings – which were almost 50 percent more than the second-most popular firm, Washington Council Ernst & Young – show the importance of patent protection to PhRMA and the drug industry. (See Table 5)

Some lobbyists were much more popular with drug companies than others. For instance, Karina Lynch, an associate at Williams & Jensen and a former lawyer for the Senate Permanent Subcommittee on Investigations, represented eight drug industry clients in 2001. (See Table 6)

## Brand-name Drug Companies Blow Away Generics in Lobbying

There are basically two kinds of companies in the pharmaceutical business: brand-name drug companies (which receive roughly 90 percent of the money that Americans spend annually on prescriptions<sup>25</sup>) and smaller generic drug makers, who often compete with the brand-name companies for market share.

Occasionally, brand-name companies and generic companies share the same lobbying agenda. For example, Barr Laboratories, one of the largest generic drugmakers, supported the pediatric exclusivity legislation because of benefits it offered to companies that brought to market the first generic version of a certain drugs. But more often the brand-name and generic companies are at odds. When that happens, the generic companies are outgunned in lobbying efforts by bigger brand-names companies.

In 2001, brand-name companies and their trade associations accounted for 97 percent of all pharmaceutical lobbying spending (\$75.7 million out of a \$78.1 million total). Brand-name companies employed nine lobbyists for every one employed by generic companies. (See below)

## Lobbying Expenditures of Brand Name and Generic Drug Companies, 2001

Drug Makers	Lobbying Expenditures	Percent of Drug Lobbying Spending	Number of Lobbyists	Percent of Lobbyists Working for Brand Name and Generic Drug Companies
Brand-Name	\$75,676,616	96.9%	927	89.7%
Generic	\$2,420,000	3.1%	107	10.3%
<b>Total</b>	<b>\$78,096,616</b>	<b>100%</b>	<b>1034*</b>	<b>100%</b>

\* The total number of lobbyists exceeds 623 because some lobbyists worked for more than one company. The 623 figure counts only the number of different individuals who worked for the industry in 2001.



## **Conclusion: Prescription for Success**

As the House Energy and Commerce and Ways and Means Committees holding hearings on the Medicare prescription benefit proposals during the week of June 17, 2002, drug industry lobbyists are expected to swarm Capitol Hill. The industry's chances of getting what they want this year from Congress once again look good.

The drug industry lobby is well-positioned to make its case to these committees: in 2001, the industry fielded 18 lobbyists who previously worked for the House Commerce Committee and 14 paid advocates that came from the House Ways and Means Committee.

In 2002, new lobbyist registrations show that the industry continues to stockpile strategic talent. For example, one of the bills that brand-name drug companies oppose most is the Greater Access to Affordable Pharmaceuticals Act (S. 812), also known as the Schumer-McCain bill after its chief sponsors, Sens. Charles Schumer (D-N.Y.) and John McCain (R-Ariz.). The bill would limit the ability of brand-name drugmakers to use legal tricks to extend the life of a monopoly patent when it is due to expire.

Sonya D. Sotak was McCain's legislative assistant for health care issues and worked on the bill – that is, until she recently became a lobbyist for the Pharmaceutical Research and Manufacturers of America.<sup>26</sup> PhRMA, which opposes the McCain-Schumer bill, says Sotak's hiring wasn't an attempt to derail the legislation.<sup>27</sup> But her defection can't help the bill.

The revolving door keeps spinning the drug industry's way: PhRMA has enlisted Joel Johnson, former Senior Adviser for Policy and Communications to President Bill Clinton. Pfizer has added Richard N. Bond, Deputy Chief of Staff to Vice President George Bush. And Amgen has bagged J. D. Derderian, staff director for the House Commerce Committee from 1995-2001.

**Table 1:  
Lobbying Expenditures and Number of Lobbyists for Top 20  
Drug Companies and Trade Groups, 2000 to 2001**

Company	2000		2001		Changes, 2000 to 2001	
	# of Lobbyists	Amount	# of Lobbyists	Amount	% Change in # of Lobbyists From 2000	% Change in Amount From 2000
Pharmaceutical Research and Manufacturers of America	67	\$7,480,000	82	\$11,280,000	22.4%	50.8%
Eli Lilly and Co.	27	\$5,300,000	58	\$6,500,000	114.8%	22.6%
Merck & Co.	23	\$5,840,000	26	\$6,200,000	13.0%	6.2%
Bristol-Myers Squibb	57	\$4,660,000	72	\$4,860,000	26.3%	4.3%
GlaxoSmithKline	32	\$3,127,000	36	\$4,000,000	12.5%	27.9%
American Home Products*	16	\$4,037,551	38	\$3,600,000	137.5%	-10.8%
Pfizer	81	\$3,440,000	82	\$3,570,000	1.2%	3.8%
Biotechnology Industry Organization	30	\$2,857,000	46	\$3,506,000	53.3%	22.7%
Johnson & Johnson	41	\$2,780,000	42	\$3,240,000	2.4%	16.5%
Amgen	44	\$2,680,000	58	\$3,080,000	31.8%	14.9%
<b>Subtotal for Top 10</b>	<b>417</b>	<b>\$43,004,000</b>	<b>540</b>	<b>\$49,836,000</b>	<b>29.5%</b>	<b>15.8%</b>
Abbott Laboratories	15	\$4,840,000	22	\$2,980,000	46.7%	-38.4%
Hoffmann-La Roche	20	\$2,422,095	17	\$2,977,938	-15.0%	22.9%
Procter & Gamble	5	\$3,541,724	9	\$2,956,713	80.0%	-16.5%
Novartis Pharmaceuticals	38	\$2,700,000	33	\$2,600,000	-13.2%	-3.7%
Aventis Pharma AG	14	\$1,560,000	42	\$2,600,000	200.0%	66.7%
Baxter International	21	\$2,480,000	26	\$2,200,000	23.8%	-11.3%
Schering-Plough	48	\$7,940,000	17	\$1,680,000	-64.6%	-78.8%
Bayer	10	\$1,336,775	6	\$1,418,125	-40.0%	6.1%
Pharmacia	31	\$3,782,960	31	\$1,337,840	0.0%	-64.6%
Genentech	28	\$1,240,000	34	\$1,280,000	21.4%	3.2%
<b>Totals</b>	<b>637**</b>	<b>\$74,045,105</b>	<b>777**</b>	<b>\$71,866,616</b>	<b>21.9%</b>	<b>-2.9%</b>
Other 32 Drug Companies and Trade Groups				\$6,230,000		
<b>Total Number of Industry Lobbyists and Amount Spent</b>			<b>623**</b>	<b>\$78,096,616**</b>		

\* The lobby disclosure report for the second half of 2001 for American Home Products (now known as "Wyeth") was still not available in the Senate on-line system as of June 5, 2002. The company's 2001 expenditure total is a projection based on the company's lobbying in the first half of 2001. (Mid-year lobbying expenditures were doubled to get a total for the full year.)

\*\* The total number of lobbyists employed by the top 20 pharmaceutical companies and trade groups exceeds 623 because some lobbyists worked for more than one company. The 623 figure counts only the number of different individuals who worked for the industry in 2001. The total amount spent comprises lobbying expenditures for 52 companies and trade groups.

Source: Public Citizen analysis of Lobby Disclosure reports filed with the Secretary of the Senate and Clerk of the House pursuant to the Lobby Disclosure Act of 1995.

**Table 2:  
Drug Company Lobbying by Year (1997-2001)**

<b>Company</b>	<b>1997</b>	<b>1998</b>	<b>1999</b>	<b>2000</b>	<b>2001</b>
Abbott Laboratories	\$893,300	\$1,877,147	\$6,789,000	\$4,840,000	\$2,980,000
Agouron Pharmaceuticals	\$20,000	\$40,000	\$64,000	\$94,600	-
Allergan	\$170,000	\$370,000	\$400,000	\$90,000	\$300,000
Alpharma USPD					\$10,000
American Home Products*	\$2,500,000	\$2,210,000	\$2,460,000	\$4,037,551	\$3,600,000
Amgen	\$1,240,000	\$2,360,000	\$3,440,600	\$2,680,000	\$3,080,000
ANDRX Pharmaceuticals					\$140,000
Anesta	-	\$60,000	\$20,000	-	-
Astra Merck	\$150,000	\$216,000	-	-	-
AstraZeneca	\$940,000	\$1,020,000	\$220,000	\$640,000	\$470,000
Aventis	-	-	\$210,000	-	-
Aventis Pasteur	-	-	\$40,000	-	\$460,000
Aventis Pharma AG	-	-	\$310,000	\$1,560,000	\$2,600,000
Barr Laboratories	\$160,000	\$234,721	\$180,000	\$120,000	\$840,000
Baxter International	\$980,000	\$960,000	\$1,720,000	\$2,480,000	\$2,200,000
Bayer	\$1,055,621	\$540,000	\$1,109,918	\$1,336,775	\$1,418,125
Becton, Dickinson and Co.	\$480,000	\$620,000	\$650,000	\$1,042,713	-
Biogen	-	\$100,000	\$166,000	\$460,000	\$350,000
Biotech Research and Develop. Corp.	\$42,000	\$22,000	\$21,000	\$137,500	-
Biotechnology Industry Organization	\$1,276,549	\$1,703,990	\$2,558,796	\$2,857,000	\$3,506,000
Biovail Corp. International	-	\$200,000	\$50,000	\$20,000	\$40,000
Boehringer Ingelheim	\$20,000	\$40,000	\$60,000	\$120,000	\$120,000
Boston Scientific	-	\$20,000	\$160,000	\$230,000	-
Bristol-Myers Squibb	\$3,780,000	\$2,820,579	\$3,620,000	\$4,660,000	\$4,860,000
Cell Therapeutics	\$100,000	\$120,000	\$120,000	\$100,000	\$40,000
Cellcor	\$20,000	-	-	-	-
Centocor	\$260,000	\$140,000	\$280,000	-	-
Connaught Laboratories	\$200,000	\$200,000	\$200,000	-	-
Consumer Healthcare Products Assn. (formerly Nonprescription Drug Manufctrs. Assn.)	\$1,320,000	\$820,000	\$460,000	\$340,000	\$220,000
Cook Group	\$410,000	\$215,000	\$220,000	\$130,000	-
Coulter Pharmaceutical	-	\$60,000	-	-	-
Council on Radionuclides and Radiopharmaceuticals	\$260,000	\$240,000	\$280,000	\$260,000	-
Dow Chemical	\$1,500,000	\$1,480,000	\$1,480,000	\$1,800,000	-
DuPont Merck Pharmaceuticals	\$415,000	-	\$40,000	-	-
DuPont Pharmaceuticals	-	\$350,000	\$400,000	\$200,000	\$120,000
Duramed Pharmaceuticals	\$60,000	-	-	\$10,000	-
Eli Lilly and Co.	\$3,836,442	\$5,160,000	\$4,130,000	\$5,300,000	\$6,500,000

Eon Laboratories					\$20,000
Fedn. of Amer. Soc. for Expermnt. Bio.	\$240,000	\$270,000	\$320,000	\$70,000	-
Genentech	\$1,360,000	\$1,060,000	\$1,040,000	\$1,240,000	\$1,280,000
Generic Pharmaceutical Assn. (GPhA)	\$320,000	\$290,000	\$340,000	\$540,000	\$480,000
Genzyme	\$760,000	\$589,000	\$760,000	\$1,000,000	\$920,000
GlaxoSmithKline	\$3,774,000	\$3,120,000	\$2,739,116	\$3,127,000	\$4,000,000
Hoechst Marion Roussel, AG	\$1,160,000	\$60,000	\$785,000	\$20,000	-
Hoffmann-La Roche	\$1,395,400	\$1,678,000	\$1,911,620	\$2,422,095	\$2,977,938
ICN Pharmaceuticals	\$160,000	\$160,000	\$40,000	\$10,000	\$100,000
Immunex	\$40,000	\$160,000	\$200,000	\$220,000	\$300,000
IMS Health					\$120,000
Indigo Medical	-	-	\$140,000	-	-
Interneuron Pharmaceuticals	\$320,000	-	-	-	-
IVAX (Zenith Goldline)					\$220,000
Johnson & Johnson	\$1,860,000	\$1,580,000	\$1,560,000	\$2,780,000	\$3,240,000
Kensley Nash	\$6,045	\$20,000	\$10,000	\$20,000	-
Knoll Pharmaceutical	\$14,000	-	\$80,000	\$60,000	-
Mallinckrodt Group	\$120,000	\$120,000	\$120,000	\$60,000	\$10,000
McKesson HBOC	\$80,000	\$40,000	\$60,000	\$80,000	\$100,000
Medco Containment	\$42,378	\$41,728	\$20,000	-	-
Medeva Pharmaceuticals	\$20,000	-	-	\$40,000	\$10,000
Merck & Co.	\$5,140,000	\$5,000,000	\$5,320,000	\$5,840,000	\$6,200,000
Michigan Biotechnology Institute	\$160,000	\$185,000	\$270,000	\$1,560,000	-
Monsanto	\$4,000,000	\$4,000,000	\$4,000,000	\$4,000,000	-
Mylan Laboratories	-	\$90,000	\$35,000	\$10,000	\$20,000
National Assn. of Pharm. Manufctrs.	\$80,000	\$80,000	\$100,000	\$40,000	\$20,000
National Pharmaceutical Alliance	\$180,000	\$200,000	\$240,000	\$30,000	-
National Wholesale Druggists' Assn.	\$60,000	\$100,000	\$120,000	\$40,000	-
Novartis Pharmaceuticals	\$1,560,000	\$1,160,000	\$1,780,000	\$2,700,000	\$2,600,000
Novopharm USA	\$120,000	\$60,000	\$60,000	\$40,000	-
Organon	-	-	\$162,340	-	-
Perrigo	\$120,000	\$100,000	\$40,000	-	-
Pfizer	\$10,000,000	\$8,000,000	\$3,830,000	\$3,440,000	\$3,570,000
Pharmaceutical Research and Manufacturers of America	\$6,320,000	\$3,120,000	\$5,020,000	\$7,480,000	\$11,280,000
Pharmacia	\$1,916,512	\$2,442,980	\$3,910,400	\$3,782,960	\$1,337,840
Pharmanex	\$160,000	\$180,000	\$120,000	-	-
Procter & Gamble	\$2,950,000	\$3,180,000	\$2,960,000	\$3,541,724	\$2,956,713
Psychemedics	\$180,000	\$201,000	\$140,000	\$162,500	-
Rhone-Poulenc Rorer	\$1,640,000	\$1,220,000	\$360,000	-	-
Schering-Plough	\$2,682,508	\$4,268,000	\$9,231,000	\$7,940,000	\$1,680,000
Sepracor	-	-	\$40,000	\$520,000	\$60,000
Serono Laboratories	\$40,000	\$80,000	\$280,000	\$590,000	\$180,000
Sidmak Laboratories	\$20,000	-	-	-	\$20,000
SmithKline Beecham	\$2,600,000	\$2,680,000	\$2,600,000	\$2,860,000	-
Taro Pharmaceuticals					\$20,000
Teva Pharmaceuticals USA	\$80,000	-	-	-	\$60,000

Theragenics	-	-	\$20,000	\$20,000	\$20,000
Thermedics	\$100,000	\$40,000	\$20,000	-	-
Transkaryotic Therapies	-	\$140,000	-	\$110,000	\$20,000
Warner-Lambert	\$1,580,000	\$1,980,000	\$2,240,000	-	-
Watson Laboratories					\$420,000
Wyeth-Ayerst	-	\$140,000	\$205,743	\$380,000	-
<b>Total</b>	<b>\$75,527,755</b>	<b>\$72,035,145</b>	<b>\$85,089,533</b>	<b>\$92,322,418</b>	<b>\$78,096,616</b>

Source: Public Citizen analysis of Lobby Disclosure reports filed with the Secretary of the Senate and Clerk of the House pursuant to the Lobby Disclosure Act of 1995.

\* The lobby disclosure report for the second half of 2001 for American Home Products (now known as “Wyeth”) was still not available in the Senate on-line system as of May 30, 2002. The company’s 2001 expenditure total is a projection based on the company’s lobbying in the first half of 2001. (Mid-year lobbying expenditures were doubled to get a total for the full year.)

**Table 3:  
Former Members of Congress Lobbying for the Drug Industry, 2001**

<b>Lobbyist</b>	<b>Offices Held</b>	<b>Clients</b>
Beryl Anthony, Jr.	U.S. House of Representatives, (D-Ark.), 1978-93.	Barr Laboratories
Bill Archer	U.S. House of Representatives, (R-Texas), 1971-2000.	Schering-Plough
Birch Bayh	U.S. Senate, (D-Ind.), 1963-81.	ICN Pharmaceuticals
Bill Brewster	U.S. House of Representatives, (D-Okla.), 1991-96.	Novartis
Dennis DeConcini	U.S. Senate, (D-Ariz.), 1977-95.	Aventis; Pfizer; Pharmacia; Watson Pharmaceuticals; ANDRX
Butler Derrick	U.S. House of Representatives, (D-S.C.), 1975-94.	Biotechnology Industry Organization; Genentech; Pharmaceutical Research and Manufacturers of America; Theragenics
Tom Downey	U.S. House of Representatives, (D-N.Y.), 1975-93.	Merck & Co.
Billy Lee Evans	U.S. House of Representatives, (D-Ga.), 1977-83.	Novartis; Pfizer; Pharmacia
Vic Fazio	U.S. House of Representatives, (D-Calif.), 1979-98.	Eli Lilly and Co.; Pharmaceutical Research and Manufacturers of America; Schering-Plough
Jack Fields	U.S. House of Representatives, (R-Texas), 1981-97.	Amgen; Schering-Plough
Michael Flanagan	U.S. House of Representatives, (R-Ill.), 1995-96.	Immunex
Willis Gradison	U.S. House of Representatives, (R-Ohio), 1975-93.	Bristol-Myers Squibb; Schering-Plough
Norman Lent	U.S. House of Representatives, (R-N.Y.), 1971-93.	Pfizer
James Lightfoot	U.S. House of Representatives, (R-Iowa), 1985-97.	Sidmark Laboratories
Bob Livingston	U.S. House of Representatives, (R-La.), 1977-99.	Pharmacia
Tom Loeffler	U.S. House of Representatives, (R-Texas), 1978-86.	Bristol-Myers Squibb
Anthony Moffett	U.S. House of Representatives, (D-Conn.), 1975-83.	Pharmacia
Susan Molinari	U.S. House of Representatives, (R-N.Y.), 1990-98.	Amgen; IVAX
Bill Paxon	U.S. House of Representatives, (R-N.Y.), 1989-98.	Johnson & Johnson; Pfizer
Steve Symms	U.S. Senate, (R-Idaho), 1981-93. Member, U.S. House of Representatives, 1972-81.	ANDRX; Aventis; Pfizer; Pharmacia; Watson Pharmaceuticals
Robert Walker	U.S. House of Representatives, (R-Penn.), 1977-96.	Immunex; Wyeth-Ayerst
Vin Weber	U.S. House of Representatives, (R-Minn.), 1981-93.	Eli Lilly and Co.; Pharmaceutical Research and Manufacturers of America; Schering-Plough
Alan Wheat	U.S. House of Representatives, (D-Mo.), 1983-94.	GlaxoSmithKline

Source: Public Citizen analysis of Lobby Disclosure reports filed with the Secretary of the Senate and Clerk of the House pursuant to the Lobby Disclosure Act of 1995.

**Table 4:  
Drug Industry Lobbyists and Their Revolving Door Connections, 2001**

<b>Name</b>	<b>Revolving Door Connection</b>
Cathy Abernathy	Chief of Staff, Rep. Bill Thomas (R-Calif.).
Stanley Abramson	Associate General Counsel, Environmental Protection Agency.
Richard Agnew	Chief Minority Counsel, House Committee on Interior and Insular Affairs, 1985-91.
Donald Alexander	Chairman, Internal Revenue Service Exempt Organizations Advisory Group, 1987-89. Commissioner, Coal Leasing Commission, Department of Interior, 1983-84. Member, Commission on Federal Paperwork, 1975-77.
Edwin Allen	Minority Counsel, House Energy and Commerce Committee.
Karen Anderson	Congressional Liaison, Environmental Protection Agency, 1997-98. Regional Coordinator, Office of Political Affairs, The White House, 1993-95.
Beryl Anthony, Jr.	Member, U.S. House of Representatives, (D-Ark.), 1978-93.
Bill Archer	Member, U.S. House of Representatives, (R-Texas), 1971-2000.
Jeanne Archibald	General Counsel, Treasury Department, 1986-93. Associate General Counsel, Office of the U.S. Trade Representative, 1980-86. Professional Staff Member, House Ways and Means Subcommittee on Trade, 1975-80.
G. Lawrence Atkins	Republican Staff Director, Senate Aging Committee.
Thomas Ault	Director, Bureau of Policy Development, Health Care Financing Administration.
Gregory Babyak	Chief of Staff, Rep. James Scheuer (D-N.Y.).
Doug Badger	Chief of Staff, Sen. Don Nickles (R-Okla.).
Grant Bagley	Director, Coverage and Analysis Group, Office of Clinical Standards and Quality, Health Care Financing Administration.
George Baker	Attorney, Office of Hearings and Appeals, Energy Department.
Haley Barbour	Director, Office of Political Affairs, The White House, 1985-87.
Michael Bartlett	Professional Staff Member, House Budget Committee, 1993-97.
Peter Barton Hutt	Chief Counsel, Food and Drug Administration, 1971-75.
Michael Bates	Counsel, House Energy and Commerce Committee, Transportation Subcommittee.
Edward Baxter	Chief Counsel and Staff Director, Subcommittee on Patents, Copyrights and Trade Marks, Senate Judiciary Committee.
Birch Bayh	Member, U.S. Senate, (D-Ind.), 1963-81.
Philip Bechtel	Chief Counsel, Senate Banking Committee, 1997-98. Legislative Director and General Counsel, Sen. Alfonse D'Amato, 1990-95.
David Beier	Chief Domestic Policy Advisor, Vice President Al Gore.
Emily Beizer	Legislative Director, Rep. Calvin Dooley (D-Calif.).
Alan Bennett	Legislative Assistant, Sen. Jacob Javits (R-N.Y.).
Douglas Bennett	Majority Counsel (1995) and Minority Counsel (1989-95), House Energy and Commerce Committee.
Jeffrey Bergner	Staff Director, Senate Foreign Relations Committee, 1985-86. Administrative Assistant (1983-84), Legislative Director (1981-82) and Legislative Assistant (1978-80), Sen. Richard Lugar (R-Ind.).
Michael Berman	Aide, Vice President Walter Mondale.
Cynthia Berry	Legislative Assistant, Rep. Jon Kyl (R-Ariz.).
Matt Berzok	Legislative Assistant, Rep. Bart Stupak (D-Mich.).
Brian Bieron	Policy Director, House Rules Committee, 1998-2001. Legislative Assistant, Rep. David

	Dreier (R-Calif.), 1993-98.
Roger Blauwet	Tax Counsel, Sen. Max Baucus (D-Mont.).
David Bockorny	Special Assistant to the President for Legislative Affairs, The White House, Reagan Administration.
Holly Bode	Special Assistant, Deputy Assistant Secretary for Legislative Affairs, Department of Health and Human Services, 1994-99. Health Care Advisor, Rep. Sander Levin (D-Mich.), 1993-94. Staff Member, Senate Special Committee on Aging, 1986-93.
John Bode	Assistant Secretary for Food and Consumer Services, Department of Agriculture, 1983-89.
Thomas Boggs	Coordinator, National Defense Executive Reserve, The White House, 1965-66. Economist, Joint Economic Committee, 1961-65.
Kent Bonham	Deputy Chief of Staff, Sen. Chuck Hagel (R-Neb.).
Katie Braden	Legislative Assistant, Sen. Bill Frist (R-Tenn.).
Robert Bradner	Administrative Assistant and Counsel (1995-2000), Chief of Staff (1990-93), Legislative Director (1987-90) and Legislative Assistant (1985-87), Rep. John Porter (R-Ill.).
Charles Brain	Senior Adviser, House Ways and Means Committee, Rep. Charles Rangel (D-N.Y.), 2001. Deputy Assistant for Legislative Affairs, House Liaison Office, Clinton Administration. Aide, Rep. Dan Rostenkowski (D-Ill.).
Bill Brewster	Member, U.S. House of Representatives, (D-Okla.), 1991-96.
Michael Bromberg	Legislative Assistant and Administrative Assistant, Rep. Herbert Tenzer (D-N.Y.), 1966-69.
Kevin Brosch	Special Advisor on International Trade, Senate Agriculture, Nutrition and Forestry Committee, 1999-2000. Special Senior Trade Advisor to the Director of Trade Policy, Foreign Agriculture Service, 1998-99.
Paul Brown	Floor Assistant, Sen. Tom Daschle (D-S.D.).
Barry Brown	Chief of Staff, Rep. Kay Granger (R-Texas).
Lance Bultena	Counsel, Subcommittee on Consumer Affairs, Foreign Commerce and Tourism, Senate Commerce Committee.
William Burke	Legislative Director, Rep. Patrick Kennedy (D-R.I.), 1994-2000.
Jack Burkman	Legislative Counsel, Rep. Rick Lazio (R-N.Y.).
James Burnley	Secretary (1987-98), Deputy Secretary (1983-87) and General Counsel (1983), Department of Transportation. Associate Deputy Attorney General, Department of Justice, 1982-83.
Thaddeus Burns	Attache and Associate Solicitor, Office of the U.S. Trade Representative, 1997-99. Associate Solicitor, U.S. Patent and Trademark Office. Clerk, Judge Karen Williams, U.S. Court of Appeals for the 4th Circuit, 1994-95.
Nicholas Calio	Assistant to the President for Legislative Affairs (1992) and Deputy Assistant to the President for House Legislative Affairs (1989-91), The White House.
Jeanne Campbell	Legislative Director and Press Secretary, Rep. Margaret Heckler (R-Mass.), 1980. Staff Assistant, Rep. Dan Rostenkowski (D-Ill.), 1978.
Steve Carey	Legislative Director, Sen. Tim Hutchinson (R-Ark.), 1998-2000. Assistant, Sen. Carl Pursell (R-Mich.).
Stacy Carlson	Transition Policy Adviser, Department of Treasury, 2000-01. Western Region Political Director, George W. Bush Presidential Campaign, 2000. Staff Director, Rep. Bill Thomas (R-Calif.).
Don Carlson	Aide, Reps. Bill Archer (R-Texas), 1971-2000, Donald Riegle (R-Mich.), 1967, James



	Harvey (R-Mich.), 1967-70.
Michael Carozza	Deputy Commissioner, Policy and External Affairs, Social Security Administration.
David Castagnetti	Chief of Staff, Sen. Max Baucus (D-Mont.). Chief of Staff, Rep. Norman Mineta (D-Calif.).
Kirsten Chadwick	Executive Assistant, Office of Legislative Affairs, The White House, Bush I Administration.
Steven Champlin	Executive Director, House Democratic Caucus, 1991-93. Executive Floor Assistant, House Majority Whip, 1987-91.
Karen Chiccehitto	Senior Policy Analyst, Assistant Chief of Staff and Director of Administration, Speaker Newt Gingrich (R-Ga.).
Bill Clark	Staff, Executive Office of the President, Office of Personnel, Bush II Administration.
Leo Coco	Deputy Assistant Secretary for Intergovernmental Relations and Corporate Affairs, Department of Education. Chief of Staff, Rep. Lloyd Doggett (D-Texas), 1995-99. Floor Assistant, Chief Deputy Whip Butler Derrick (D-S.C.), 1991-95.
Howard Cohen	Counsel, House Commerce Committee, 1988-99.
Dana Colarulli	Legal Intern and Fellow, Sen. Maria Cantwell (D-Wash.).
Keith Cole	Counsel, Senate Small Business Committee.
Nina Collier	Legislative Assistant, Sen. Slade Gorton (R-Wash.), 1995-98.
Samantha Cook	Senior Legislative Assistant, Rep. Roy Blunt (R-Mo.).
Doral Cooper	Assistant U.S. Trade Representative, Office of U.S. Trade Representative. Economist, Division of International Finance, Federal Reserve.
Shawn Coughlin	Professional Staff, House Ways and Means Health Subcommittee, 1995-96. Senior Health Policy Advisor, Rep. Nancy Johnson (R-Conn.), 1994-95. Legislative Assistant, Rep. Fred Grandy (R-Iowa), 1991-94.
Melissa Coyle	Chief Negotiator on Tariffs and Market Access Issues, Office of U.S. Trade Representative. Director, Office of Mexico, Department of Commerce. Trade Expert, House Ways and Means Committee and National Security Council.
Daniel Crane	Legislative Director, Rep. John LaFalce (D-N.Y.) and Sen. Daniel Patrick Moynihan (D-N.Y.). Tax Counsel, Rep. Frank Guarini (D-N.J.), 1991.
David Crow	Special Assistant to Chief of Staff of Secretary, Department of Agriculture, 1985-86. Special Assistant, Rep. Thomas Coleman, (R-Mo.).
Rodger Currie	Staff Member, House Ways and Means Committee.
Dack Dalrymple	Counsel, House Subcommittee on Health and the Environment, Committee on Energy and Commerce, 1974-79. Legislative Assistant, Rep. Paul Rogers (D-Fla.), 1970 and 1973-74.
Smith Davis	Counsel, Subcommittee on Crime, House Judiciary Committee, 1978-79. Clerk, U.S. District Court, District of Columbia, 1977-78.
Thomas Davis	Office of the Chief Counsel, Internal Revenue Service, 1966-70.
Dennis DeConcini	Member, U.S. Senate, (D-Ariz.), 1977-95.
Ann Delory	Executive Assistant to the Secretary, Department of Labor, Clinton Administration. Legislative Aide, Sen. Edward Kennedy (D-Mass.).
Butler Derrick	Member, U.S. House of Representatives, (D-S.C.), 1975-94.
Barry Direnfeld	Chief Legislative Counsel, Sen. Howard Metzenbaum (D-Ohio). Chief Counsel and Staff Director, Subcommittee on Antitrust, Monopolies and Business, Senate Judiciary Committee.
Matthew Dolan	Legislative Assistant, Sen. Dave Durenberger (R-Minn.).

John Doney	Assistant Secretary, Majority of the U.S. Senate.
Tom Downey	Member, U.S. House of Representatives, (D-N.Y.), 1975-93.
Paul Drazek	Special Assistant to the Secretary, Department of Agriculture, Clinton Administration. Trade Policy and Marketing Specialist, Foreign Agricultural Service, Department of Agriculture.
Kenneth Duberstein	Deputy Chief and Chief of Staff (1987-89), Assistant to the President for Legislative Affairs (1981-83) and Deputy Assistant to the President for Legislative Affairs (1981), The White House. Deputy Under Secretary, Department of Labor, 1976-77.
Billy Lee Evans	Member, U.S. House of Representatives, (D-Ga.), 1977-83.
Eddie Evans	Health Affairs Congressional Liaison, Office of the Assistant Secretary of Defense, 1992-93. Chief, Congressional Actions Branch, Office of the Army Surgeon General, 1982-88. Senior Program Analyst, Office of the Army Surgeon General, 1987-88.
Douglas Farquar	Assistant U.S. Attorney for the District of Maryland, Department of Justice, 1990-97.
Vic Fazio	Member, U.S. House of Representatives, (D-Calif.), 1979-98.
Carl Feldbaum	Chief of Staff, Sen. Arlen Specter (R-Penn.). Inspector General, Defense Intelligence, Department of Defense, 1976-79. Assistant to the Secretary, Department of Energy, 1979-80.
Howard Feldman	Chief Counsel, Permanent Subcommittee on Investigation, Senate Committee on Government Operations, 1973-77. Attorney, Appellate Section, Tax Division, Department of Justice, 1964-68.
Jack Fields	Member, U.S. House of Representatives, (R-Texas), 1981-97.
Don Fierce	Aide, Rep. James Broyhill (R-N.C.). Professional Staff Member, Office of Congressional Affairs, General Services Administration, 1973-75.
Desiree Filippone	Legislative Assistant, Sen. Evan Bayh (D-Ind.).
Louis Finkel	Legislative Director, Rep. Bart Gordon (D-Tenn.).
Anne Finley	Chief Investigator, House Government Reform Subcommittee on Human Resources, 1995-99.
Brian Fitzgerald	Law Clerk, Senate Judiciary Committee on the Constitution.
Jayne Fitzgerald	Tax Counsel, House Ways and Means Committee, 1992-93 and 1980-85.
Ellen Fitzgibbons	Press Secretary, Rep. Micky Leland (D-Texas). Assistant Press Secretary, Speaker Thomas "Tip" O'Neill (D-Mass.).
Michael Flanagan	Member, U.S. House of Representatives, (R-Ill.), 1995-96.
Michael Forscey	Chief Minority Counsel, Senate Committee on Labor and Human Resources, 1981-85. Special Assistant, Rep. John Brademas (D-Ind.), 1980-81.
David Foster	Trade Counsel, Senate Finance Committee, 1977-81. Assistant to the Chairman (1975-77) and Attorney/Advisor (1973-75), Office of the General Counsel, International Trade Commission.
Anthony Foti	District Director, Rep. Bill Paxon (R-N.Y.), 1994-98.
David Franasiak	Staff Director, Subcommittee on Tax Oversight, House Small Business Committee, 1979-81. Aide, Rep. Henry Nowak (D-N.Y.), 1979-81.
Ronna Freiberg	Legislative Affairs Director, Office of the Vice President, Clinton Administration. Legislative Affairs Staff, The White House, Carter Administration.
Kimberley Fritts	Legislative Aide, Sen. Connie Mack III (R-Fla.).
Gary Gallant	Chief of Staff, Press Secretary and District Representative, Rep. Jim Saxton (R-N.J.), 1989-98.
Henry Gandy	White House Liaison Officer, The White House, Reagan Administration. Aide, Rep.

	Tom Loeffler (R-Texas). Aide, Rep. Trent Lott (R-Miss.).
Rob Garagiola	Aide, House Democratic Health Care Task Force, 1995-98.
Vincent Garlock	Majority Counsel, House Judiciary Subcommittee on Courts, the Internet and Intellectual Property, 1997-2001.
LaBrenda Garrett-Nelson	Senior Legislation Attorney, Joint Committee on Taxation, 1982-87.
Gary Gasper	Senior Tax Advisor (1991-93) and Assistant to the Commissioner (1989-91), Internal Revenue Service. Attorney/Advisor, U.S. Tax Court, 1983-84.
Bruce Gates	Legislative Assistant, Rep. Carroll Campbell, Jr. (R-S.C.).
Matt Gelman	Floor Assistant, Rep. David Bonior (D-Mich.). Legislative Aide, Rep. Richard Gephardt (D-Mo.).
John Gilbert	Attorney/Advisor, Office of the Chief Counsel (1993-95), and Law Clerk, Office of Administrative Judges (1992-93), Drug Enforcement Administration, Department of Justice.
Thomas Giles	Health Counsel, House Energy and Commerce Committee.
Nick Giordano	Chief Minority Tax Counsel, Senate Finance Committee, 1997-99. Legislative Director and Tax Counsel, Sen. Max Baucus (D-Mont.), 1993-95.
Steve Giuli	Legislative Director, Rep. Frank Pallone (D-N.J.).
Martin Gold	Counsel, Sen. Howard Baker, Jr. (R-Tenn.), Minority Staff Director and Counsel, Senate Rules Committee. Professional Staff, Select Senate Committee on Intelligence. Legal Assistant, Sen. Mark Hatfield (R-Ore.).
Richard Gold	Special Assistant to the Administrator, Environmental Protection Agency, 1993-94. Special Assistant, Sen. Lloyd Bentsen (D-Texas), 1991-92.
Francis Grab	Tax and Trade Counsel, Rep. Robert Matsui (D-Calif.).
Willis Gradison	Member, U.S. House of Representatives, (R-Ohio), 1975-93. Assistant to the Secretary, Department of Health, Education and Welfare, 1955-57. Assistant to the Undersecretary, Department of the Treasury, 1953-55.
C. Boyden Gray	Counsel to the President (1989-93) and Counsel to the Vice President (1981-89), The White House. Clerk, Justice Earl Warren, U.S. Supreme Court, 1968.
Karen Green	Health Counsel, Rep. Robert Matsui (D-Calif.), 1995-98. Counsel, White House Conference on Aging, 1995. Aide, Clinton/Gore Campaign, 1992.
Dave Gribbin	Director, Congressional Relations, Bush-Cheney Transition. Chief of Staff, Sen. Dan Coats (R-Ind.), 1993-96. Aide, Rep. Dick Cheney (R-Wyo.), 1979-89.
G.O. Griffith, Jr.	Special Assistant to the President for Intergovernmental Affairs, The White House, 1989-91. Assistant Secretary for Intergovernmental and Interagency Affairs, Department of Education, Bush I Administration.
Simon Gros	Legislative Assistant, Rep. Frank LoBiondo (R-N.J.).
Mara Guarducci	Legislative Assistant, Rep. James Greenwood (R-Penn.).
John Haddow	Aide, Sen. Orrin Hatch (R-Utah).
C. McClain Haddow	Campaign Manager, Sen. Orrin Hatch (R-Utah).
Robert Harding	Attorney, Securities and Exchange Commission. Special Assistant to Secretary for Congressional Affairs, Department of Health, Education and Welfare.
Bryce Harlow	Deputy Undersecretary for Legislative Affairs, Department of the Treasury, 1989-90. Special Assistant to the President for Legislative Affairs (1985-89) and Associate Director for Legislative Affairs, Office of Management and Budget, 1985-86.
Steven Hart	Special Assistant, Assistant Attorney General for Legal Policy, Department of Justice,

	1981-82. Assistant to the Chair, President's Task Force on ERISA Reorganization, Office of Management and Budget.
Vicki Hart	Special Assistant, Senate Majority Leader Bob Dole (R-Kan.) and Senate Majority Leader Trent Lott (R-Miss.).
James Hawkins	Aide, Sen. James Jeffords (I-Vt.). Professional Staff Member, Senate Health, Education, Labor and Pensions Committee.
Noelle Hawley	Legislative Director, Rep. Bill Archer (R-Texas).
Jay Heimbach	Legislative Affairs Director, Federal Communications Commission, 1999-2001.
Gary Heimberg	Attorney/Advisor, Chief Administrative Judge, Board of Contract Appeals, Department of Transportation, 1985-87.
Wallace Henderson	Chief Counsel and Chief of Staff, Rep. W.J. Tauzin (R-La.). Chief of Staff, Sen. John Breaux (D-La.), 1987-93.
Shannon Henderson	Legislative Assistant and Office Manager, Rep. Sam Johnson (R-Texas), 1991-94.
Denise Henry	Staff Member, Senate Aging Committee.
Steven Hilton	Deputy Assistant to the President and Deputy Director, Office of Public Liaison, The White House, 1993-95. Minority Chief Counsel and Staff Director, Subcommittee on the Constitution, Senate Judiciary Committee, 1987-89.
Richard Hohlt	Board of Directors, Student Loan Marketing Assn., 1990-94. Board of Directors, Overseas Private Investment Corporation, 1983-85. Board of Advisors, Peace Corps, 1982-83. Executive Assistant, Sen. Richard Lugar (R-Ind.), 1977-81.
Kathleen Holcombe	Professional Staff, House Commerce Committee, 1993-97.
Alan Holmer	Deputy Assistant to the President for Intergovernmental Affairs, The White House, Reagan Administration.
John "Brad" Holsclaw	Staff Member, Republican Leader Floor Operations, U.S. Senate, 1987-98.
Rodney Hoppe	Deputy Press Secretary, House Commerce Committee.
Teresa Houser	Staff Member, Senate Finance Committee.
Robert Hurley	Chief of Staff, Sen. John Chafee (R-R.I.). Republican Staff Director, Senate Environment and Public Works Committee, 1980-90.
Lester Hyman	Attorney, Securities and Exchange Commission, 1955-56.
Elizabeth Hyman	Attorney, Office of the U.S. Trade Representative, The White House.
Mark Isakowitz	Press Secretary, Rep. Paul Gillmor (R-Ohio).
Lee Janger	Contractor, Civic Division, Department of Justice.
Timothy Jenkins	Investigator, Subcommittee on Investigation and General Oversight, Senate Labor Committee, 1980-82.
Steve Jenning	Chief of Staff, Sen. Ron Wyden (D-Ore.), 1996-97. Staff Director, Subcommittee on Regulation, Business Opportunities and Technology, Committee on Small Business, U.S. House of Representatives, 1987-95.
Christopher Jennings	Senior Health Policy Adviser to the President, The White House, Clinton Administration.
Calvin Johnson	Senior Legislative Assistant, Sen. Richard Schweiker (R-Penn.), 1975-76.
Charles Johnson	Legal Intern, House Judiciary Committee, 1992.
Michael Johnson	Chief of Staff and Press Secretary, Rep. Robert Michel (R-Ill.).
Paul Johnson	Chief of Staff, Rep. Eugene Chappie (R-Ga.).
Ann Thomas Johnston	Legislative Assistant, Rep. Richard Burr (R-N.C.).
John Jonas	Tax Counsel, House Ways and Means Committee, 1981-86. Legislative Director, Rep. Bob Shamansky (D-Ohio), 1980-81. Legislative Counsel, Rep. Elizabeth Holtzman (D-

	N.Y.), 1978-80.
Kathryn Karol	Legislative Assistant, Sen. Evan Bayh (D-Ind.).
David Keaney	Counsel, House Commerce Committee.
Thomas Keating	Director of Policy Services and House Sergeant, Arms Control Bureau, Department of Defense.
Timothy Keating	Special Assistant to the President and Staff Director, The White House, Clinton Administration. Assistant Floor Manager, Democratic Leadership. Special Assistant to Doorkeeper, U.S. House.
Dennis Kedzior	Senior Staff Assistant, House Appropriations Committee, 1980-98. Assistant to Secretary, Department of Transportation, 1978-80. Chief of Budget Operations, House Budget Committee, 1974-77.
James Keese	Special Assistant, Sen. John Heinz (R-Penn.).
Roger Keller	Counsel, House Small Business Committee, 1999-2000.
Martha Kendrick	Professional Staff Member, Department of Health and Human Services, 1973-85.
Keith Kennedy	Majority Staff Director, Senate Appropriations Committee, 1980-96.
Jeffrey Kimbell	Aide, Sen. Howard Baker (R-Tenn.). Aide, Lawrence Eagleburger, Secretary of State, Bush I Administration.
Charles Kinney	Chief Floor Counsel, Sen. George Mitchell (D-Maine), 1989-93. Floor Counsel and Judiciary Counsel, Sen. Robert Byrd (D-W.Va.), 1974-88.
John Daniel Kiser	Special Assistant to Deputy General Counsel and Senior Attorney, Department of Health and Human Services, 1976-83.
Gary Klein	Republican Counsel, Senate Government Operations Committee, 1975-77. Legislative Assistant, Sen. Jacob Javits (R-N.Y.), 1973-75.
Jerry Klepner	Assistant Secretary for Legislative Affairs, Department of Health and Human Services, Clinton Administration.
Tom Korologos	Deputy Assistant to the President for Legislative Affairs, The White House, 1970-74. Assistant, Sen. Wallace Bennett (R-Utah).
Lisa Kountoupes	Deputy Assistant to the President for Legislative Affairs, Clinton Administration.
Bruce Kuhlik	Assistant to the Solicitor General, Department of Justice, 1984-86. Law Clerk to Judge Levin Campbell, U.S. Court of Appeals, First Circuit, 1981-82.
Jeffrey Kushan	Attorney/Advisor, Office of Legislative and International Affairs (1997-98 and 1991-95) and Biotech Patent Examiner (1987-91), U.S. Patent and Trademark Office, Department of Commerce.
Ed Kutler	Assistant, Rep. Newt Gingrich (R-Ga.), 1992-97.
Stephen Lacey	Assistant, Senate Agriculture, Nutrition and Forestry Committee.
Jennifer Larkin	Legislative Director, Rep. Robert Dornan (R-Calif.), 1991-96.
Dave Larson	Health Policy Analyst, Sen. Bill Frist (R-Tenn.)
Steve Lawton	Chairman, Advisory Commission on Childhood Vaccines, Department of Health and Human Services, 1989-90. Chief Counsel, House Subcommittee on Health and the Environment, 1971-78.
Susan Lent	Counsel, Subcommittee on Surface Transportation, Committee on Transportation and Infrastructure, 1996-98.
Norman Lent	Member, U.S. House of Representatives, (R-N.Y.), 1971-93.
Norman Lent III	Legislative Assistant, Sen. Connie Mack (R-Fla.).
Kenneth Levine	Director, Office of Congressional Consumer and Public Affairs, Federal Energy Regulatory Commission, Department of Energy, 1979-81. Deputy Assistant Secretary

	for Legislation, Department of Health, Education and Welfare, 1977-79.
Rita Lewis	Aide, Sen. Thomas Daschle (D-S.D.).
James Lightfoot	Member, U.S. House of Representatives, (R-Iowa), 1985-97.
Kim Linthicum	Legislative Director, Rep. Bob Franks (R-N.J.)
Drew Littman	Policy Director, Sen. Barbara Boxer (D-Calif.).
Bob Livingston	Member, U.S. House of Representatives, (R-La.), 1977-99.
Tom Loeffler	Member, U.S. House of Representatives, (R-Texas), 1978-1986. Assistant to the President for Central American Legislative Affairs, The White House, 1987.
G. Thomas Long	Counsel and Health Policy Advisor, Sen. Dan Coats (R-Ind.).
Jorge Lopez, Jr.	Legal Adviser, Bill Clinton Presidential Campaign, 1991-92.
Ann-Marie Lynch	Staff Director, Subcommittee on Health (1998-2000) and Professional Staff (1997-98), House Ways and Means Committee. Economist, Health Care Financing Administration, 1990-95.
Karina Lynch	Counsel to Senate Permanent Subcommittee on Investigations, Committee on Government Affairs, 1999-2000. Investigative Counsel to Senate Special Committee on Aging, 1997-99.
Matthew Lyons	Legislative Director, Rep. Earl Hillard (D-Ala.). Staff Member, House Commerce Committee.
Jeffrey MacKinnon	Legislative Director, Rep. Joe Barton (R-Texas), 1985-93.
Lauren Maddox	Senior Communications Adviser, House Speaker Newt Gingrich (R-Ga.).
Paul Magliocehetti	Professional Staff Member, Subcommittee on Defense, House Appropriations Committee. Professional Staff Member, General Accounting Office.
Karen Marangi	Counsel, Rep. Patrick Leahy (D-Vt.).
Allen Martin	Chief of Staff, Rep. Bob Livingston (R-La.).
Warren Maruyanna	Associate Director, International Economic Policy (1992-93) and Deputy Associate Director (1989-92), Office of Policy Development, The White House. Associate General Counsel, Office of the U.S. Trade Representative, 1983-89.
Jim Mathews	Chief of Staff, Rep. Thomas Manton (D-N.Y.), 1997-99. Deputy Assistant Administrator, Environmental Protection Agency, 1995-97.
Daniel Mattoon	Deputy Chairman, National Republican Congressional Committee.
Marshall Matz	Special Counsel, Senate Agriculture, Nutrition and Forestry Committee, 1978-80. Counsel and General Counsel, Senate Select Committee on Nutrition and Human Needs, 1973-77.
Steve McBee	National Security Assistant, Rep. Norm Dicks (D-Wash.). Legislative Assistant, Rep. Al Swift (D-Wash.). Senior Policy Aide, Rep. Maria Cantwell (D-Wash.).
Kevin McGuinness	Chief of Staff, Sen. Orrin Hatch (R-Utah) and Republican Staff Director, Senate Committee of Labor and Human Resources
Marty McGuinness	Associate to Rep. Pete Sessions (R-Texas), House Rules Committee.
Patrick McLain	Counsel, House Energy and Commerce Committee.
John McMackin	Chairman, Private Litigation Committee, Federal Bar Association, 1984-85.
Kathleen Means	Chief Health Care Analyst, Senate Finance Committee, 1998-2001. Senior Health Insurance Policy Analyst, House Ways and Means Committee, 1995-96. Director of Executive Operations, Health Care Financing Administration.
Charles Mellody	Aide, House Ways and Means Committee, 1984-94.
Richard Meltzer	Chief Minority Counsel, Select Subcommittee on Iranian Arms Transfers to Bosnia, 1996. Chief Counsel, House Committee on Natural Resources, 1991-94. Chief

	Legislative Assistant, Abner Mikva (D-Ill.), 1975-79.
Daniel Meyer	Chief of Staff, Rep. Newt Gingrich (R-Ga.), 1989-96. Administrative Assistant, Rep. Vin Weber (R-Minn.), 1986-89. Legislative Director (1982-86), Legislative Assistant (1980-82) and Projects Director (1979), Sen. Rudy Boschwitz (R-Minn.).
Denny Miller	Administrative Assistant, Sen. Henry Jackson (D-Wash.), 1968-83. Professional Staff Member, Senate Energy and Natural Resources Committee.
Mark Mioduski	Aide, Subcommittee on Labor, Health and Human Services and Education, House Appropriations Committee.
Diane Moery	Legislative Director, Sen. Don Nickles (R-Okla.).
Anthony Moffett	Member, U.S. House of Representatives, (D-Conn.), 1975-83.
Susan Molinari	Member, U.S. House of Representatives, (R-N.Y.), 1990-98.
Loren Monroe	Legislative Aide, Sen. Pete Domenici (R-N.M.).
Walter Moore	Chief of Staff, Rep. David Price (D-N.C.).
Elizabeth Morra	Communications Director, House Appropriations Committee, 1995-2000. Press Secretary, Sen. Thad Cochran (R-Miss.).
Timothy Morrison	Associate Director, Presidential Personnel.
Phil Moseley	Chief of Staff (1995-96) and Republican Chief of Staff (1988-94), House Ways and Means Committee. Administrative Assistant, Rep. Bill Archer (R-Texas), 1973-88.
Rick Murphy	Legislative Assistant, Sen. Judd Gregg (R-N.H.).
James Musser	Aide, Rep. Jim Bunning (R-Ky.).
Patricia Nelson	Staff Member, House Ways and Means Committee.
Robert Neuman	Press Secretary, Campaign Advisor and Chief of Staff, Rep. Morris Udall (D-Ariz.).
Darryl Nirenberg	Chief of Staff, Sen. Jesse Helms (R-N.C.), 1991-95. Deputy Staff Director (1990-91), Associate Minority Counsel (1989-90) and Professional Staff Member (1987-88), Senate Foreign Relations Committee.
Michael O'Brien	Legislative Assistant, Sen. Dan Coats (R-Ind.).
Lawrence O'Brien, III	Deputy for Tax Legislation to the Assistant Secretary for Legislative Affairs, Department of Treasury, 1977-79.
G. John O'Hanlon	Aide, Rep. Richard Gephardt (D-Mo.).
Joseph O'Leary	Congressional Staff, 1969-75.
Joe O'Neill	Administrative Assistant, Sen. Lloyd Bentsen (D-Texas), 1978-84.
George Olsen	Member, Rules Advisory Committee, U.S. Court of Veterans Appeals.
Jonathan Orloff	Legislative Assistant, Sen. Edward Kennedy (D-Mass.), 1977-86.
Stuart Pape	Executive Assistant to the Commissioner (1978-79) and Associate Chief Counsel (1974-78), Food and Drug Administration.
Eugene Patrone	Aide, Rep. Susan Molinari (R-N.Y.).
Bill Paxon	Member, U.S. House of Representatives, (R-N.Y.), 1989-98.
Layna Peltier	Legislative Assistant, Rep. James Lightfoot (R-Iowa).
James Phelps	Trial Attorney, Office of the Chief Counsel, Food and Drug Administration. Assistant U.S. Attorney for the District of Columbia, Department of Justice.
William Phillips	Chief of Staff (1983-86), Legislative Director and Legislative Assistant (1981-83), Sen. Ted Stevens (R-Alaska).
James Pickup	Legislative Assistant and Budget Associate, Rep. Anthony Beilenson (D-Calif.).
Mark Planning	Staff Member, House Appropriations Committee, 1988-89. Senior Legislative Assistant, Rep. Stan Parris (R-Va.), 1983-86.
Jon Plebani	Chief of Staff, Majority Whip William Gray III (D-Penn.). Deputy Special Advisor on

	Haiti, The White House, Clinton Administration.
Anthony Podesta	Counsel, Sen. Edward M. Kennedy (D-Mass.). Assistant U.S. Attorney for the District of Columbia, Department of Justice.
Franklin Polk	Staff Director, Senate Finance Committee.
David Quam	Counsel, Subcommittee on the Constitution, Federalism and Property Rights, Senate Judiciary Committee, 1994-96.
Patrick Quinn	Chief of Staff, Deputy Administrator and Associate Administrator for Congressional Affairs, Environmental Protection Agency, 1986-92.
John Raffaelli	Tax and Trade Counsel, Sen. Lloyd Bentsen (D-Texas), 1980-84.
Pat Raffaniello	Chief of Staff, Rep. Bill Brewster (D-Okla.).
Stacy Rampy	Health Care Aide, Rep. Anna Eshoo (D-Calif.).
Lee Rawls	Chief of Staff, Sen. Bill Frist (R-Tenn.), 1997-2000. Chief of Staff, Sen. Pete Domenici (R-N.M.), 1982-85.
Brenda Reese	Conference Coordinator, House Republican Conference.
Steve Ricchetti	Deputy Chief of Staff and Deputy Assistant for Senate Legislative Affairs, The White House, 1993-2001.
Anthony Roda	Director of Legislative Strategy, Rep. Newt Gingrich (R-Ga.), 1989-92. Legislative Director, Rep. Steve Gunderson (R-Wisc.), 1987-88.
Edward Rogers, Jr.	Deputy Assistant to the President (1989-91) and Senior Deputy Political Director (1987), The White House.
Mark Rokala	Agricultural Legislative Assistant, Rep. David Minge (D-Minn.). Appropriations Staff Member, Sen. Herbert Kohl (D-Wisc.).
Romano Romani	Chief of Staff, Sen. Dennis DeConcini (D-Ariz.). Legislative Director and Staff Director, Sen. Vance Harke (D-Ind.).
Patrick Ronan	Senior Legislative Assistant, Rep. John Peterson (R-Penn.). Aide, Rep. John Ensign (R-Nev.). Aide, Rep. Jon Christensen (R-Neb.).
Thomas Rosenkoetter	Legislative Assistant, Rep. Bill McCollum (R-Fla.), 1993-97.
Lisa Ross	Director, Office of Public Liaison, Department of Labor.
Alan Roth	Minority Staff Director and Chief Counsel, House Commerce Committee, 1995-97. Majority Staff Director and Chief Counsel (1992-95) and Counsel (1985-92), House Committee on Energy and Commerce.
Bob Rozen	Legislative Counsel (1989-94) and Legislative Assistant (1985-89), Sen. George Mitchell (D-Maine). Legislative Assistant, Sen. Wendell Ford (D-K.Y.), 1980-85.
Peter Rubin	Legislative Director, Rep. Jim McDermott (D-Wash.).
David Rudd	Administrative Assistant, Sen. Ernest Hollings (D-S.C.).
Thomas Ryan	Chief Counsel (1985-87) and Counsel (1977-84), House Committee on Energy and Commerce.
Timothy Sanders	Clerk (1996-98) and Staff Member (1983-95), Subcommittee on Agriculture, House Appropriations Committee.
Albert Saunders	Administrative Assistant, Sen. Muriel Humphrey (D-Minn.), 1978. Director of Legislation, Sen. Hubert Humphrey (D-Minn.), 1971-78.
Peter Scher	Special Trade Negotiator for Agriculture and Food Policy, Office of U.S. Trade Representative, The White House, 1998-2000. Chief of Staff, Department of Commerce, 1995-97.
Melissa Schulman	Policy Director, Rep. Steny Hoyer (D-Md.), 1995-98. Floor Assistant and Executive Director, House Democratic Caucus, 1990-94. Legislative Aide, Rep. Thomas Manton



	(D-N.Y.), 1985. Staff Assistant, Rep. Geraldine Ferraro (D-N.Y.).
William Schultz	Deputy Assistant Attorney General, Department of Justice, 1998-2000. Deputy Commissioner for Policy, Food and Drug Administration, Department of Health and Human Services, 1994-98.
Victor Schwartz	Executive Director, Federal Interagency Counsel on Insurance, 1978-80. Chairman, Federal Interagency Task Force on Product Liability, 1976-80.
Paul Scolese	Professional Staff Member, House Commerce Committee, 1997 to 2000.
Michael Scrivner	Chief of Staff (1986-93) and Legislative Director (1981-86), Rep. Norman Lent (R-N.Y.). Legislative Assistant, Rep. John Duncan, Sr. (R-Tenn.), 1978-81.
Dennis Shea	Counsel and Deputy Chief of Staff, Sen. Bob Dole (R-Kan.).
Andrew Shoyer	Legal Advisor, U.S. Mission to the World Trade Organization. Assistant General Counsel, Office of the U.S. Trade Representative, 1990-97.
Stephen Sims	Deputy Staff Director, Subcommittee on Oversight and Investigations, House Energy and Commerce Committee, 1976-92.
Linda Skladany	Acting Chairman (1989-91) and Commissioner (1989-91), Occupational Safety and Health Review Commission. Special Assistant to the President and Deputy Director, White House Office of Public Liaison, 1985-87.
Barney Skladany	Member, Bush-Cheney Transition, 2000-01. Professional Staff Member, Criminal Division, Department of Justice. Clerk, Judge George Hart Jr., U.S. District Court for the District of Columbia.
Gare Smith	Deputy Assistant Secretary, Department of State.
Larry Smith	Sergeant at Arms (1983-85) and Deputy Sergeant at Arms (1981-83), U.S. Senate. Staff Director, Senate Rules Committee.
Dale Snape	Staff, Office of Management and Budget.
Paul Snyder	Tax Counsel, Rep. Ed Jenkins (D-Ga.), 1989-92. Legislative Assistant, Speaker Thomas "Tip" O'Neill, Jr. (D-Mass.), 1979-85.
Daniel Spiegel	United States' Permanent Representative, United Nations, 1994-96.
Harry Sporidis	Senior Legislative Aide, Rep. James Greenwood (R-Penn.).
Diedre Stach	Budget Analyst, House Science Committee, 1995-96. Legislative Director (1989-95), Legislative Assistant (1989), Legislative Correspondent (1988-89) and Junior Caseworker (1987-88), Rep. Bob Walker (R-Penn.).
Donna Steele-Flynn	Staff Director, Subcommittee on Oversight, House Ways and Means Committee, 1994-98. Legislative Director, Rep. Bill Archer (R-Texas), 1988-94.
Deborah Steelman	Associate Director for Human Resources, Veterans and Labor, Office of Management and Budget, 1986-87. Deputy Assistant to the President and Director of Intergovernmental Affairs, The White House, 1985.
J. Vander Stoep	Chief of Staff, Sen. Slade Gorton (R-Wash.). Member, Washington State House of Representatives, 1980-86.
Ryan Stroschein	Legislative Counsel, Sen. Tom Daschle (D-S.D.).
Sandi Stuart	Assistant Secretary for Legislative Affairs, Department of Defense, 1993-99. Chief of Staff, Rep. Vic Fazio (D-Calif.), 1987-93.
Scott Styles	Chief of Staff, Rep. Pete Sessions (R-Texas).
Thomas Susman	General Counsel, Subcommittee on Antitrust, Senate Judiciary Committee, 1977-78. General Counsel, Counsel and Chief Counsel, Subcommittee on Administrative Practices and Procedures.
Steve Symms	Member, U.S. Senate, (R-Ind.), 1981-93. Member, U.S. House of Representatives (R-

	Ind.), 1972-81.
Richard Tarplin	Assistant Secretary for Legislation, Department of Health and Human Services. Staff Director, Subcommittee on Children, Family, Drugs and Alcoholism. Professional Staff Member, Senate Labor and Human Resources Committee.
Linda Tarplin	Special Assistant to the President for Legislative Affairs (Senate), The White House, Bush I Administration.
Jeffrey Tassej	Counsel, Subcommittee on Commerce, Consumer and Monetary Affairs, 1990-92. Legislative Director, Rep. Drueie Douglas Barnard, Jr., (D-Ga.).
Nancy Taylor	Health Policy Director, Senate Committee on Labor and Human Resources. Aide, Sen. Orrin Hatch (R-Utah).
Peter Teeley	U.S. Ambassador to Canada. Press Secretary, Vice President, The White House, 1980-85. Press Secretary, Sen. Jacob Javits (R-N.Y.), 1974-77.
Henry Terhune	Associate Staff Member, House Rules Committee, 1984-87. Legislative Assistant and Director, Rep. Butler Derrick (D-S.C.), 1979-87.
Craig Thorn	Director, Europe, Africa, Middle East Division, U.S. Department of Agriculture, 1996-98.
William Timmons, Jr.	Assistant to the President, The White House, 1969-74. Administrative Assistant, Rep. William Brock (R-Tenn.), 1963-69. Assistant, Sen. Alexander Wiley (R-Wisc.), 1955-62.
Darla Tomes	Field Representative, Rep. Ron Lewis (R-Ky.).
Michael Tongour	Chief Counsel, Sen. Alan Simpson (R-Wyo.), 1989-94. Legislative Director, Sen. Strom Thurmond (R-S.C.), 1986-87. Counsel, Senate Committee on Labor and Human Resources, 1985-86.
Jim Tozzi	Deputy Administrator, Office of Management and Budget.
Brad Traverse	Legislative Assistant, Sen. Barry Goldwater (R-Ariz.).
Timothy Trysla	Legislative Aide, Rep. Bill Archer (R-Texas), 1990-94.
Arthur Tsien	Associate Chief Counsel for Veterinary Medicine and Enforcement, Food and Drug Administration, 1980-85.
James Tucker, Jr.	Legislative Counsel, Rep. Bob Inglis (R-S.C.), 1997-99.
Timothy Urban	Legislative Assistant, Rep. Wally Herger (R-Calif.), 1982-96.
Anne Urban	Legislative Director and Tax Advisor, Sen. Bob Kerrey (D-Neb.). Chief Advisor for Tax, Trade and Appropriations, Sen. Joseph Lieberman (D-Conn.).
Joseph Vasapoli	Trial Attorney, Federal Energy Regulatory Commission, Department of Energy, 1992. Republican Counsel, House Commerce Committee, 1985-89. Special Assistant to the Commissioner, Federal Energy Regulatory Commission, 1984-85.
Jay Velasquez	Counsel, Sen. Kay Bailey Hutchinson (R-Texas). General Counsel, Sen. Phil Gramm (R-Texas), National Republican Senatorial Campaign Committee.
Ann Morgan Vickery	Director, Executive Secretariat, Department of the Treasury, 1975-78. Researcher and Staff Assistant, The White House, 1969-74.
Bill Viney	Aide, Rep. Scott Klug (R-Wisc.).
Beth Viola	Senior Environmental Advisor to the President, The White House.
Frank Vlossak	Legislative Assistant, Rep. Merrill Cook (R-Utah), 1997-98.
John Waits	Chief of Staff, Rep. David Bowen (D-Miss.), 1980-82. Counsel, House Agriculture Committee, 1979-80.
Robert Walker	Member, U.S. House of Representatives, (R-Penn.), 1977-96.
William Walters	Staff, Subcommittee on Health, House Ways and Means Committee.

Vin Weber	Member, U.S. House of Representatives, (R-Minn.), 1981-93.
David Weeda	Associate Chief Counsel, Food and Drug Administration, 1976-81.
Michael Wessel	General Counsel, Rep. Richard Gephardt (D-Mo.), 1977-98.
Fowler West	Staff Director, House Agriculture Committee. Commissioner, Commodities Futures Trading Commission.
Anne Wexler	Assistant to the President for Public Liaison, The White House, Carter Administration.
Mary Whalen	Staff Member, Senate Committee on Veterans' Affairs. Legislative Analyst, Congressional Research Service.
Alan Wheat	Member, U.S. House of Representatives, (D-Mo.), 1983-94.
Richard White	Legislative Coordinator, Sen. John Chaffee (R-R.I.), 1989-90.
David Whitestone	Associate Staff, Rep. Frank Wolf (R-Va.), Subcommittee on Transportation, House Committee on Appropriations.
Cynthia Wilkinson	Counsel, House Commerce Committee, 1995-97. Chief Counsel, Subcommittee on Merchant Marine. Research Assistant, Subcommittee on Coast Guard and Navigation. Executive Assistant, Rep. Mario Biaggi (D-Texas), 1971-79.
J.D. Williams	Captain, Judge Advocate General Corps. Assistant, Sen. Robert Kerr (D-Okla.).
Tony Williams	Chief of Staff, Sen. Slade Gorton (R-Wash.).
JoAnn Willis	Legislative Assistant, Sen. Dave Durenburger (R-Minn.), 1993-94. Health Policy Advisor, Rep. Jay Alex McMillan (R-N.C.), 1991-93. Manager (1980-90) and Staff Member (1976-80), Social Security Administration.
S. Bruce Wilson	International Trade Negotiator, Office of the U.S. Trade Representative, 1975-91.
John Winburn	Aide, Reps. Tom Gettys (D-S.C.) and Kenneth Holland (D-S.C.).

Source: Public Citizen analysis of Lobby Disclosure reports filed with the Secretary of the Senate and Clerk of the House pursuant to the Lobby Disclosure Act of 1995.

**Table 5:  
Top Outside Firms with Biggest Clients, 2001**

<b>Firm/Biggest Clients</b>	<b>Amount</b>
<b>Powell, Goldstein, Frazer &amp; Murphy</b>	<b>\$1,980,000</b>
Pharmaceutical Research & Manufacturers of America	\$1,440,000
Genentech	\$340,000
Biotechnology Industry Organization	\$180,000
<b>Washington Council Ernst &amp; Young</b>	<b>\$1,340,000</b>
Aventis	\$660,000
Baxter Healthcare Corp.	\$200,000
Johnson & Johnson	\$200,000
<b>Williams &amp; Jensen, PC</b>	<b>\$1,220,000</b>
American Home Products	\$340,000
Pharmaceutical Research & Manufacturers of America	\$300,000
Genentech	\$160,000
<b>Hogan &amp; Hartson</b>	<b>\$970,000</b>
Pharmaceutical Research & Manufacturers of America	\$540,000
Amgen	\$160,000
GlaxoSmithKline	\$100,000
<b>Patton Boggs</b>	<b>\$940,000</b>
Hoffmann LaRoche	\$660,000
Bristol-Myers Squibb	\$240,000
<b>The Wexler Group</b>	<b>\$720,000</b>
American Home Products	\$300,000
Immunex	\$240,000
Hoffmann LaRoche	\$180,000
<b>Akin, Gump, Strauss, Hauer &amp; Feld</b>	<b>\$680,000</b>
Pfizer	\$280,000
Johnson & Johnson	\$240,000
<b>HC Associates</b>	<b>\$610,000</b>
Pharmaceutical Research & Manufacturers of America	\$180,000
Merck & Co.	\$120,000
American Home Products	\$120,000
<b>Verner, Liipfert, Bernhard, McPherson &amp; Hand</b>	<b>\$580,000</b>
Amgen	\$360,000
Pharmaceutical Research & Manufacturers of America	\$180,000
<b>The Legislative Strategies Group</b>	<b>\$550,000</b>
Hoffmann LaRoche	\$140,000
Biogen	\$120,000
Amgen	\$120,000

Source: Public Citizen analysis of Lobby Disclosure reports filed with the Secretary of the Senate and Clerk of the House pursuant to the Lobby Disclosure Act of 1995.

**Table 6:  
Most Popular Drug Industry Lobbyists in 2001 and Their  
Revolving Door Connections**

# of Clients	Name	Former Positions
8	Karina Lynch	Counsel, Senate Permanent Subcommittee on Investigations, Committee on Government Affairs, 1999-2000. Investigative Counsel, Senate Special Committee on Aging, 1997-99.
8	George Olsen	Member, Rules Advisory Committee, U.S. Court of Veterans Appeals.
7	Howard Cohen	Counsel, House Commerce Committee, 1988-99.
6	Kathleen Holcombe	Professional Staff, House Commerce Committee, 1993-97.
5	Denise Henry	Staff Member, Senate Aging Committee.
5	Steve Jenning	Chief of Staff, Sen. Ron Wyden (D-Ore.), 1996-97. Staff Director, Subcommittee on Regulation, Business Opportunities and Technology, House Committee on Small Business, 1987-95.
5	Jayne Fitzgerald	Tax Counsel, House Ways and Means Committee, 1992-93 and 1980-85.
5	Marty McGuinness	Associate, Rep. Pete Sessions (R-Texas).
5	Bruce Gates	Legislative Assistant, Rep. Carroll Campbell, Jr. (R-S.C.).
5	Layna Peltier	Legislative Assistant, Rep. Jim Lightfoot (R-Iowa).
5	Timothy Urban	Legislative Assistant, Rep. Wally Herger (R-Calif.), 1982-96.
5	Nick Giordano	Chief Minority Tax Counsel, Senate Finance Committee, 1997-99. Legislative Director and Tax Counsel, Sen. Max Baucus (D-Mont.), 1993-95.
5	Ronna Freiberg	Legislative Affairs Director, Office of the Vice President, Clinton Administration. Legislative Affairs Staff, The White House, Carter Administration.
5	Phil Moseley	Chief of Staff (1995-96) and Republican Chief of Staff (1988-94), House Ways and Means Committee. Administrative Assistant, Rep. Bill Archer (R-Texas), 1973-88.
5	Thomas Giles	Health Counsel, Energy and Commerce Committee.
5	Larry Smith	Sergeant at Arms (1983-85) and Deputy Sergeant at Arms (1981-83), U.S. Senate. Staff Director, Senate Rules Committee.
5	LaBrenda Garrett-Nelson	Senior Legislation Attorney, Joint Committee on Taxation, 1982-87.
5	Richard Meltzer	Chief Minority Counsel, Select Subcommittee on Iranian Arms Transfers to Bosnia, 1996. Chief Counsel, House Committee on Natural Resources, 1991-94. Chief Legislative Assistant, Abner Mikva (D-Ill.), 1975-79.
5	James Hawkins	Aide, Sen. James Jeffords (I-Vt.). Professional Staff Member, Senate Health, Education, Labor and Pensions Committee.
5	Bob Rozen	Legislative Counsel (1989-94) and Legislative Assistant (1985-89), Sen. George Mitchell (D-Maine). Legislative Assistant, Sen. Wendell Ford (D-Ky.), 1980-85.
5	Deborah Steelman	Associate Director for Human Resources, Veterans and Labor, Office of Management and Budget (1986-87) and Deputy Assistant to the President and Director, Intergovernmental Affairs (1985), The White House.

5	Michael Bartlett	Professional Staff Member, House Budget Committee, 1993-97.
5	John Doney	Assistant Secretary, Majority of the U.S. Senate.
5	Gary Gasper	Senior Tax Advisor (1991-93) and Assistant to the Commissioner (1989-91), Internal Revenue Service. Attorney/Advisor, U.S. Tax Court, 1983-84.
5	Shawn Coughlin	Professional Staff, House Ways and Means Health Subcommittee, House Ways and Means Committee, 1996-96. Senior Health Policy Advisor, Rep. Nancy Johnson (R-Conn.), 1994-95. Legislative Assistant, Rep. Fred Grandy (R-Iowa), 1991-94.
5	Martin Gold	Counsel, Sen. Howard Baker, Jr. (R-Tenn.), Minority Staff Director and Counsel, Senate Rules Committee. Professional Staff, Select Senate Committee on Intelligence. Legal Assistant, Sen. Mark Hatfield (R-Ore.).
5	Doug Badger	Chief of Staff, Sen. Don Nickles (R-Okla.).
5	Donna Steele-Flynn	Staff Director, Subcommittee on Oversight, House Ways and Means Committee, 1994-98. Legislative Director, Rep. Bill Archer (R-Texas), 1988-94.
4	Melissa Schulman	Policy Director, Rep. Steny Hoyer (D-Md.), 1995-98. Floor Assistant and Executive Director, House Democratic Caucus, 1990-94. Legislative Aide, Rep. Thomas Manton (D-N.Y.), 1985. Staff Assistant, Rep. Geraldine Ferraro (D-N.Y.).
4	Frank Vlossak	Legislative Assistant, Rep. Merrill Cook (R-Utah), 1997-98.
4	David Castagnetti	Chief of Staff, Sen. Max Baucus (D-Mont.). Chief of Staff, Rep. Norman Mineta (D-Calif.).
4	Brenda Reese	Conference Coordinator, House Republican Conference.
4	Michael Bromberg	Legislative Assistant and Administrative Assistant, Rep. Herbert Tenzer (D-N.Y.), 1966-69.
4	Jeffrey Bergner	Staff Director, Senate Foreign Relations Committee, 1985-86. Administrative Assistant (1983-84), Legislative Director (1981-82) and Legislative Assistant (1978-80), Sen. Richard Lugar (R-Ind.).
4	David Bockorny	Special Assistant to the President for Legislative Affairs, The White House, Reagan Administration.
4	Ann Morgan Vickery	Director, Executive Secretariat, Department of the Treasury, 1975-78. Researcher and Staff Assistant, The White House, 1969-74.
4	Simon Gros	Legislative Assistant, Rep. Frank LoBiondo (R-N.J.).
4	Charles Brain	Senior Adviser, House Ways and Means Committee, Rep. Charles Rangel (D-N.Y.), 2001. Deputy Assistant for Legislative Affairs, House Liaison Office, Clinton Administration. Aide, Rep. Dan Rostenkowski (D-Ill.).
4	Scott Styles	Chief of Staff, Rep. Pete Sessions (R-Texas).

Source: Public Citizen analysis of Lobby Disclosure reports filed with the Secretary of the Senate and Clerk of the House pursuant to the Lobby Disclosure Act of 1995.

**Table 7:  
Drug Industry Lobbyists, 2001**

<b>Name</b>	<b>Firm</b>	<b>Client(s)</b>
Cathy Abernathy	Cathy Abernathy Consultants	Pharmaceutical Research and Manufacturers of America
Stanley Abramson	Arent Fox Kintner Plotkin & Kahn	Biotechnology Industry Organization
Richard Agnew	Van Ness Feldman	McKesson HBOC
William Albers	Albers & Co.	Eli Lilly & Co.
Donald Alexander	Akin, Gump, Strauss, Hauer & Feld	Johnson & Johnson
Edwin Allen	MARC Associates	Boehringer Ingelheim Pharmaceuticals
Kevin Allen	The Washington Group	IVAX
Jeffrey Anders	Biogen; Jeffrey M. Anders	Biogen; Bristol-Myers Squibb; Merck & Co.; Procter & Gamble
Karen Anderson	Long Aldridge & Norman	Biotechnology Industry Organization
John Angus	The Duberstein Group	Pharmacia
Beryl Anthony, Jr.	Winston and Strawn	Barr Laboratories
L. Nicole Antorcha	Amgen	In-House
Bill Archer	PricewaterhouseCoopers	Schering-Plough
Jeanne Archibald	Hogan & Hartson	Pharmaceutical Research and Manufacturers of America
G. Lawrence Atkins	Health Policy Analysts	Schering-Plough
Thomas Ault	Health Policy Alternatives	Johnson & Johnson; Pharmaceutical Research and Manufacturers of America
Gregory Babyak	Royer & Babyak	Genentech
Eve Bachrach	Consumer Healthcare Products Assn.	In-House
Doug Badger	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Grant Bagley	Arnold & Porter	Novartis; American Home Products
Greg Bailey	Katcher Vaughn & Bailey Communications	Pharmaceutical Research and Manufacturers of America
George Baker	Williams & Jensen, PC	AstraZeneca Pharmaceuticals
Russel Bantham	Pharmaceutical Research and Manufacturers of America	In-House
Haley Barbour	Barbour Griffith & Rogers	Amgen; Bristol-Myers Squibb; GlaxoSmithKline
Mark Barmak	Abbott Laboratories	In-House
Michael Bartlett	Kessler & Associates Business Services	Amgen; Novartis; Pfizer; Pharmacia; GlaxoSmithKline
Peter Barton Hutt	Covington & Burling	Consumer Health Care Products Assn.
Michael Bates	Timmons and Co.	Bristol-Myers Squibb
Edward Baxter	Parry, Romani, DeConcini & Symms	ANDRX; Aventis; Pfizer; Pharmacia; Watson Pharmaceuticals
Marguerite Baxter	Pharmacia	In-House
Birch Bayh	Venable, Baetjer, Howard & Civiletti	ICN Pharmaceuticals
Lauren Bazel	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly &

		Co.; Johnson & Johnson; Pfizer
Philip Bechtel	Williams & Jensen, PC	Pharmaceutical Research and Manufacturers of America
Mark Behrens	Shook, Hardy & Bacon	Eli Lilly & Co.
David Beier	Hogan & Hartson	Bristol-Myers Squibb; Genentech; Pharmaceutical Research and Manufacturers of America
Emily Beizer	Mayer, Brown, Rowe & Maw	Pharmacia
Judith Bello	Pharmaceutical Research and Manufacturers of America	In-House
Alan Bennett	Bennett, Turner & Coleman	Bristol-Myers Squibb; Serono Holdings
Catherine Bennett	Pfizer	In-House
Douglas Bennett	Timmons and Co.	Bristol-Myers Squibb
Edith Bennett	Pacific Consulting Associates	Allergan
Jeffrey Bergner	Bergner Bockorny Castagnetti Hawkins & Brain	Biogen; Bristol-Myers Squibb; Genzyme; GlaxoSmithKline
Michael Berman	The Duberstein Group	Pharmacia
Cynthia Berry	The Wexler Group	American Home Products; Hoffmann LaRoche; Immunex; IMS Health
Matt Berzok	Ryan, Phillips, Utrecht & MacKinnon	Pfizer
Brian Bieron	Clark & Weinstock	Eli Lilly & Co.; Pharmaceutical Research and Manufacturers of America
Bill Black	Fleishman-Hillard	Abbott Laboratories
Victoria Blatter	Merck & Co.	In-House
Roger Blauwet	Canfield & Associates	American Home Products; Merck & Co.; Pfizer
David Bockorny	Bergner Bockorny Castagnetti Hawkins & Brain	Biogen; Bristol-Myers Squibb; Genzyme; GlaxoSmithKline
Holly Bode	BKSH & Associates	Bristol-Myers Squibb; GlaxoSmithKline
John Bode	Olsson, Frank and Weeda, PC	Eon Laboratories; National Association of Pharmaceutical Manufacturers; Taro Pharmaceuticals
Thomas Boggs	Patton Boggs	Bristol-Myers Squibb
Don Bohn	Johnson & Johnson	In-House
Karin Bolte	Heidepriem & Mager	American Home Products
Tom Bombelles	Merck & Co.	In-House
Kent Bonham	Clark & Weinstock	Eli Lilly & Co.; Pharmaceutical Research and Manufacturers of America
Jay Bonitt	Eli Lilly & Co.	In-House
April Boston	Canfield & Associates	American Home Products; Merck & Co.; Pfizer
Donna Boswell	Hogan & Hartson	Biotechnology Industry Organization; Genentech; GlaxoSmithKline
M. Kenneth Bowler	Pfizer	In-House
Katie Braden	Fierce & Isakowitz	Generic Pharmaceutical Assn.
Gary Bradford	Allergan	In-House
Robert Bradner	Holland & Knight	American Home Products



Charles Brain	Bergner Bockorny Castagnetti Hawkins & Brain	Biogen; Bristol-Myers Squibb; Genzyme; GlaxoSmithKline
Carolyn Brehm	Procter and Gamble	In-House
Kyl Brenner	DTB Associates	Biotechnology Industry Organization
Bill Brewster	R. Duffy Wall & Associates	Novartis
Michael Bromberg	Capitol Health Group	Abbott Laboratories; Bristol-Myers Squibb; Johnson & Johnson; Pfizer
Kevin Brosch	DTB Associates; Powell, Goldstein, Frazer & Murphy	Alpharma USPD; Biotechnology Industry Organization
Barry Brown	Alpine Group	Biotechnology Industry Organization
Jessie Brown	Brown and Associates	Eli Lilly & Co.
Paul Brown	PodestaMattoon	Genentech; Genzyme; Serono Laboratories
Bill Broydrick	Broydrick & Associates	Abbott Laboratories; Barr Laboratories
Cynthia Broydrick	Broydrick & Associates	Barr Laboratories
John Buchanan	PodestaMattoon	Genzyme
Rich Buckley	Eli Lilly & Co.	In-House
Lance Bultena	Hogan & Hartson	Genentech; Pharmaceutical Research and Manufacturers of America
Deborah Bumbaugh	Novartis	In-House
M. Brooke Bumpers	Hogan & Hartson	Biotechnology Industry Organization
William Burke	The Washington Group	Amgen; IVAX
Jack Burkman	Holland & Knight	American Home Products
James Burnley	Winston and Strawn	Barr Laboratories
Brian Burns	Hoffmann-La Roche	In-House
Thaddeus Burns	Akin, Gump, Strauss, Hauer & Feld	American Home Products; Pfizer
Fran Butler	Heidepriem & Mager	American Home Products
Nicholas Calio	The OB-C Group	Biotechnology Industry Organization
Jeanne Campbell	Campbell-Crane & Associates	Merck & Co.
Anne Canfield	Canfield & Associates	American Home Products; Merck & Co.; Pfizer
Gary Capistrant	US Strategies	IVAX
Brian Carey	Foley, Hoag & Eliot	Amgen; Biogen; Genzyme; Pharmaceutical Research and Manufacturers of America
Steve Carey	US Strategies	IVAX
Don Carlson	PricewaterhouseCoopers	Schering-Plough
Stacy Carlson	Akin, Gump, Strauss, Hauer & Feld	Pfizer
Nancy Carlton	Merck & Co.	In-House
Michael Carozza	Bristol-Myers Squibb	In-House
Bruce Carroll	Johnson & Johnson	In-House
Dan Casserly	Novartis	In-House
David Castagnetti	Bergner Bockorny Castagnetti Hawkins & Brain	Biogen; Bristol-Myers Squibb; Genzyme; GlaxoSmithKline
Kirsten Chadwick	The OB-C Group	Biotechnology Industry Organization
Steven Champlin	The Duberstein Group	Pharmacia
Julia Chaney	Fleishman-Hillard	Abbott Laboratories
Irene F. Chang	Hogan & Hartson	Pharmaceutical Research and Manufacturers of America

Karen Chiccehitto	BKSH & Associates	Bristol-Myers Squibb; GlaxoSmithKline
Bill Clark	PodestaMattoon	Genzyme; Serono Laboratories
Steve Clark	Steve Clark	Barr Laboratories
Vern Clark	Vern Clark and Associates	Amgen
James Claudin	PodestaMattoon	Genzyme
Kate Clemans	Crowell & Moring	Novartis
Leo Coco	Powell, Goldstein, Frazer & Murphy	Biotechnology Industry Organization; Pharmaceutical Research and Manufacturers of America; Theragenics
Roy Coffee	O'Connor & Hannan	Amgen
Daniel Cohen	Loeffler, Jonas & Tuggey	Bristol-Myers Squibb
Howard Cohen	Greenberg Traurig; HC Associates	American Home Products; Amgen; Baxter Healthcare Corp.; Eli Lilly & Co.; Genzyme; Merck & Co.; Pharmaceutical Research and Manufacturers of America
Sharon Cohen	Biotechnology Industry Organization	In-House
Dana Colarulli	Verner, Liipfert, Bernhard, McPherson & Hand	Biovail Corp. International
Keith Cole	Swidler Berlin Shereff Friedman	Aventis Pharmaceuticals; Transkaryotic Therapies
Nina Collier	Washington 2 Advocates	Immunex
Judy Cook	Aventis Pharma AG	In-House
Samantha Cook	Fierce & Isakowitz	Generic Pharmaceutical Assn.
Doral Cooper	Crowell & Moring	Novartis
Stephen Cooper	R. Duffy Wall & Associates	Novartis
Sarah Costin	Marwood Group	Bristol-Myers Squibb
Shawn Coughlin	Capitol Health Group; Steelman Health Strategies	Abbott Laboratories; Bristol-Myers Squibb; Johnson & Johnson; Pfizer; Pharmaceutical Research and Manufacturers of America
Melissa Coyle	Crowell & Moring	Novartis
Daniel Crane	Campbell-Crane & Associates	Merck & Co.
David Crow	DC Legislative and Regulatory Services	Biotechnology Industry Organization
Rodger Currie	Pharmaceutical Research and Manufacturers of America	In-House
Dack Dalrymple	Dalrymple & Associates	Aventis Pasteur; Biotechnology Industry Organization
Mary Frances Daly	GlaxoSmithKline	In-House
Kristi Daniels	Ogilvy Public Relations Worldwide	Merck & Co.
Randall Davis	Stuntz, Davis & Staffier	Pharmaceutical Research and Manufacturers of America
Smith Davis	Akin, Gump, Strauss, Hauer & Feld	Pfizer
Thomas Davis	Davis & Harman	Pharmaceutical Research and Manufacturers of America
Dennis DeConcini	Parry, Romani, DeConcini & Symms	ANDRX; Aventis; Pfizer; Pharmacia; Watson Pharmaceuticals

Ann Delory	PodestaMattoon	Genentech; Serono Laboratories
Amy Demske	Broydrick & Associates	Barr Laboratories
Butler Derrick	Powell, Goldstein, Frazer & Murphy	Biotechnology Industry Organization; Genentech; Pharmaceutical Research and Manufacturers of America; Theragenics
Elise Deschenes	Pharmaceutical Research and Manufacturers of America	In-House
Barry Direnfeld	Swidler Berlin Shereff Friedman	Aventis Pharmaceuticals
Ronald Docksai	Bayer	In-House
Matthew Dolan	Baker & Hostetler	Eli Lilly & Co.
Nancy Donaldson	Downey McGrath Group	Merck & Co.
John Doney	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Cathy Dooley	Johnson & Johnson	In-House
Tom Downey	Downey McGrath Group	Merck & Co.
David Drake	Novartis	In-House
Paul Drazek	DTB Associates	Alpharma USPD; Biotechnology Industry Organization
Kenneth M. Duberstein	The Duberstein Group	Pharmacia
Molly Duncan	Procter and Gamble	In-House
Melissa Edwards	The Washington Group	Amgen
James Elkin	Novartis	In-House
Brad Enzl	R. Duffy Wall & Associates	Novartis
Randall Erben	Randall H. Erben	Genentech
Brent Erickson	Biotechnology Industry Organization	In-House
Markham Erickson	McGuinness & Holch	Barr Laboratories
Billy Lee Evans	Kessler & Associates Business Services	Novartis; Pfizer; Pharmacia
Eddie Evans	Aventis Pharma AG	In-House
Douglas Farquar	Hyman, Phelps & McNamara	Medeva Pharmaceuticals
Jane Fawcett-Hoover	Procter and Gamble	In-House
Vic Fazio	Clark & Weinstock	Eli Lilly & Co.; Pharmaceutical Research and Manufacturers of America; Schering-Plough
Lila Feisee	Biotechnology Industry Organization	In-House
Carl Feldbaum	Biotechnology Industry Organization	In-House
Howard Feldman	Van Ness Feldman, A Professional Corp.	McKesson HBOC
Shelley Fichtner	Van Ness Feldman, A Professional Corp.	McKesson HBOC
Jack Fields	Vern Clark and Associates	Amgen; Schering-Plough
Don Fierce	Fierce & Isakowitz	Generic Pharmaceutical Assn.
Desiree Filippone	Eli Lilly & Co.	In-House
Louis Finkel	Lent Scrivner & Roth	Pfizer
Anne Finley	Biotech Policy Group	Bayer
Brian Fitzgerald	Swidler Berlin Shereff Friedman	Aventis Pharmaceuticals; Transkaryotic Therapies

David Fitzgerald	Powell, Goldstein, Frazer & Murphy	Biotechnology Industry Organization; Genentech
Jayne Fitzgerald	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Ellen Fitzgibbons	Timmons and Co.	Bristol-Myers Squibb
Laurie-Ann Flanagan	DC Legislative and Regulatory Services	Biotechnology Industry Organization
Michael Flanagan	The Wexler Group	Immunex
Michael Forsey	Forsey & Stinson	Barr Laboratories
David Foster	Biogen	In-House
Anthony Foti	Akin, Gump, Strauss, Hauer & Feld	Pfizer
David Franasiak	Williams & Jensen, PC	Genentech
Sara Franko	The Legislative Strategies Group; Hoffmann-La Roche	Amgen; Biogen; Eli Lilly & Co.; Hoffman-LaRoche; Novartis
Mark Franz	Loeffler, Jonas & Tuggey	Bristol-Myers Squibb
Ronna Freiberg	The Legislative Strategies Group	Amgen; Biogen; Eli Lilly & Co.; Hoffman-LaRoche; Novartis
Kimberley Fritts	PodestaMattoon	Serono Laboratories
Elizabeth Fuller	Baxter Healthcare Corp.	In-House
Tripp Funderburk	The Washington Group	Amgen; IVAX
Pamela Furman	Olsson, Frank and Weeda, PC	National Association of Pharmaceutical Manufacturers
Michael Galano	Holland & Knight	American Home Products
Gary Gallant	Swidler Berlin Shereff Friedman	Transkaryotic Therapies
Larry Games	Procter and Gamble	In-House
Henry Gandy	The Duberstein Group	Pharmacia Corp.
Rob Garagiola	Greenberg Traurig	Genzyme
Vincent Garlock	Verner, Liipfert, Bernhard, McPherson & Hand	Biovail Corp. International
LaBrenda Garrett-Nelson	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Gary Gasper	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Bruce Gates	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Junia Geisler	Ogilvy Public Relations Worldwide	Merck & Co.
Matt Gelman	PodestaMattoon	Genentech; Genzyme; Serono Laboratories
Jacqui Genovesi	Procter and Gamble	In-House
Elena Giberga	Patton Boggs	Bristol-Myers Squibb
L Val Giddings	Biotechnology Industry Organization	In-House
John Gilbert	Hyman, Phelps & McNamara, PC	Hoffmann-La Roche; Medeva Pharmaceuticals
Thomas Giles	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Michael Gillis	Holland & Knight	American Home Products
Nick Giordano	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Steve Giuli	Generic Pharmaceutical Assn.	In-House

Robert Glennon	Williams & Jensen, PC	Abbott Laboratories; AstraZeneca Pharmaceuticals; Genentech
Martin Gold	The Legislative Strategies Group	Amgen; Biogen; Eli Lilly & Co.; Hoffman-LaRoche; Novartis
Richard Gold	Holland & Knight	American Home Products
Jacques Gorlin	Gorlin Group	Bristol-Myers Squibb; Pfizer; Pharmaceutical Research and Manufacturers of America
Elizabeth Goss	Bennett, Turner & Coleman	Abbott Laboratories; AstraZeneca LP; Bristol-Myers Squibb; Eli Lilly & Co.; Johnson & Johnson/Ortho Biotech; Novartis; Pfizer
Francis Grab	Washington Council Ernst & Young	Baxter Healthcare Corp.; Pfizer
Willis Gradison	Patton Boggs	Bristol-Myers Squibb; Schering-Plough
Rebecca Gradler	Pharmaceutical Research and Manufacturers of America	In-House
Pamela Graves-Moore	Pharmacia Corp.	In-House
C. Boyden Gray	Wilmer, Cutler & Pickering	Amgen; Genzyme
Karen Green	Akin, Gump, Strauss, Hauer & Feld	American Home Products; Serono Laboratories
Kaylene Green	The PMA Group	Biogen; Generic Pharmaceutical Assn.; Pharmaceutical Research and Manufacturers of America
Sarah Gregg	Baxter Healthcare Corp.	In-House
Edward Greissing, Jr.	Pharmacia	In-House
Dave Gribbin	Clark & Weinstock	Pharmaceutical Research and Manufacturers of America
G.O. Griffith, Jr.	Barbour Griffith & Rogers	Amgen; GlaxoSmithKline
Sarah Groothuis	Patton Boggs	Bristol-Myers Squibb
Simon Gros	Kessler & Associates Business Services	Novartis; Pfizer; Pharmacia; GlaxoSmithKline
Susan Grymes	Olsson, Frank and Weeda, PC	Eon Laboratories; National Association of Pharmaceutical Manufacturers; Taro Pharmaceuticals
Mara Guarducci	Pharmaceutical Research and Manufacturers of America	In-House
Nance Guenther-Peterson	US Strategies	IVAX
Rosemary Haas	Abbott Laboratories	In-House
C. McClain Haddow	C. McClain Haddow	Mylan Laboratories
John Haddow	Parry, Romani, DeConcini & Symms	ANDRX; Aventis; Pfizer; Pharmacia; Watson Pharmaceuticals
Sarah Haller	Novartis	In-House
Todd Halpern	Buchanan Ingersoll	Sidmark Laboratories
Matt Haney	Katcher Vaughn & Bailey Communications	Pharmaceutical Research and Manufacturers of America
Jake Hansen	Barr Laboratories	In-House
Robert Harding	McDermott, Will & Emery	Eli Lilly & Co.
Bryce Harlow	Timmons and Co.	Bristol-Myers Squibb
Karen Harned	Olsson, Frank and Weeda, PC	Eon Laboratories; National Association of

		Pharmaceutical Manufacturers; Taro Pharmaceuticals
Steven Hart	Williams & Jensen, PC	Genentech; Pharmaceutical Research and Manufacturers of America
Vicki Hart	Verner, Liipfert, Bernard, McPherson & Hand; Bob Dole Enterprises	Amgen; Johnson & Johnson; Pharmaceutical Research and Manufacturers of America
Scott Hatch	Parry, Romani, DeConcini & Symms	ANDRX; Aventis; Pfizer; Pharmacia; Watson Pharmaceuticals
James Hawkins	Bergner Bockorny Castagnetti Hawkins & Brain	Amgen; Biogen; Bristol-Myers Squibb; Genzyme; GlaxoSmithKline
Jay Hawkins	Biogen	In-House
Noelle Hawley	Verner, Liipfert, Bernard, McPherson & Hand	Amgen
Jay Heimbach	Ricchetti Inc.	Eli Lilly & Co.; Novartis; Pharmacia
Gary Heimberg	Akin, Gump, Strauss, Hauer & Feld	Johnson & Johnson; Pfizer; Serono Laboratories
Shannon Henderson	Parry, Romani, DeConcini & Symms	ANDRX; Aventis; Pfizer; Pharmacia; Watson Pharmaceuticals
Wallace Henderson	Public Strategies	Aventis Pharmaceuticals
Denise Henry	The Legislative Strategies Group; Biogen	Amgen; Biogen; Eli Lilly & Co.; Hoffman-LaRoche; Novartis
Shannon Herzfeld	Pharmaceutical Research and Manufacturers of America	In-House
Steven Hilton	Buchanan Ingersoll	Sidmark Laboratories
Jody Hoffman	The Wexler Group	American Home Products; Hoffmann LaRoche; Immunex Corp.; IMS Health
Richard Hohlt	Richard F. Hohlt	Bristol-Myers Squibb Co.
Kathleen Holcombe	Policy Directions	Amgen; Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Merck & Co.; Pharmaceutical Manufacturers and Researchers of America
Alan Holmer	Pharmaceutical Research and Manufacturers of America	In-House
John "Brad" Holsclaw	Tongour Simpson Holsclaw Green	Aventis Pharmaceuticals; Pharmaceutical Research and Manufacturers of America
Jocelyn Hong	Twenty-First Century Group	Schering-Plough
Rodney Hoppe	Ryan, Phillips, Utrecht & MacKinnon	Pfizer
Teresa Houser	Powell, Goldstein, Frazer & Murphy	Theragenics
Erin Huntington	Eli Lilly & Co.	In-House
Robert Hurley	Arnold & Porter	Amgen; Novartis
Elizabeth Hyman	Akin, Gump, Strauss, Hauer & Feld	American Home Products
Lester Hyman	Swidler Berlin Shereff Friedman	Transkaryotic Therapies
Mark Isakowitz	Fierce & Isakowitz	Generic Pharmaceutical Assn.
Alvin Jackson	Bergner Bockorny Castagnetti Hawkins & Brain	Biogen; Bristol-Myers Squibb; Genzyme; GlaxoSmithKline
Julia James	Health Policy Alternatives	Pharmaceutical Research and Manufacturers of

		America
Lee Janger	Columbus Public Affairs	TEVA Pharmaceuticals
Leo Jardot	American Home Products	In-House
Linda Jenckes	Kessler & Associates Business Services	Amgen; Novartis; Pfizer; Pharmacia
Ed Jenkins	Hooper Owen & Winburn	Pfizer
Missy Jenkins	Pharmaceutical Research and Manufacturers of America	In-House
Timothy Jenkins	O'Connor & Hannan	Amgen
Steve Jenning	Capitol Health Group, LLC; Steelman Health Strategies	Abbott Laboratories; Bristol-Myers Squibb; Johnson & Johnson; Pfizer; Pharmaceutical Research and Manufacturers of America
Christopher Jennings	Christopher Charles Jennings	Generic Pharmaceutical Assn.
Darrel Jodrey	Johnson & Johnson	In-House
Calvin Johnson	McDermott, Will & Emery	Allergan
Charles Johnson	Akin, Gump, Strauss, Hauer & Feld	Pfizer
Michael Johnson	The OB-C Group	Biotechnology Industry Organization
Paul Johnson	Fleishman-Hillard	Abbott Laboratories
Ann Thomas Johnston	R. Duffy Wall & Associates	Novartis
Jake Johnston	Immunex	In-House
Jeremy Johnston	Immunex.	In-House
John Jonas	Patton Boggs	Bristol-Myers Squibb; Hoffmann-La Roche
W. James Jonas, III	Loeffler, Jonas & Tuggey	Bristol-Myers Squibb
J. Robert Joyce	Akin, Gump, Strauss, Hauer & Feld	American Home Products; Pfizer
Dolly Judge	Pfizer	In-House
Kathryn Karol	Eli Lilly & Co.	In-House
Bronwen Kaye	American Home Products Corp.	In-House
David Keaney	Bristol-Myers Squibb	In-House
Thomas Keating	The OB-C Group	Biotechnology Industry Organization
Timothy Keating	Timmons and Co.	Bristol-Myers Squibb
Dennis Kedzior	The PMA Group	Pharmaceutical Research and Manufacturers of America
James Keese	Columbus Public Affairs	TEVA Pharmaceuticals
Roger Keller	Winston and Strawn	Barr Laboratories
Martha Kendrick	Patton Boggs	Hoffmann-La Roche
Barbara Kennedy	Baker & Hostetler	Eli Lilly & Co.
Keith Kennedy	Baker, Donelson, Bearman & Caldwell, P.C.	Amgen
J. H. Kent	Kent & O'Connor	GlaxoSmithKline
Richard Kessler	Kessler & Associates Business Services	Amgen; Novartis; Pfizer; Pharmacia; GlaxoSmithKline
Frederick Killion	Winston and Strawn	Barr Laboratories
Jeffrey Kimbell	Jeffrey J. Kimbell & Associates	Sepracor
Rachel King	Novartis	In-House
Charles Kinney	Winston and Strawn	Barr Laboratories
Janie Kinney	GlaxoSmithKline	In-House

John Daniel Kiser	Foxkiser	Bristol-Myers Squibb
Gary Klein	Verner, Liipfert, Bernard, McPherson & Hand	Amgen; Biovail Corp. International
Jerry Klepner	BKSH & Associates	Bristol-Myers Squibb; Genetech; GlaxoSmithKline
Cathy Koch	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Robbie Koch	Verner, Liipfert, Bernard, McPherson & Hand	Amgen
Eleanor Kolton	Greenberg Traurig	Genzyme
Tom Korologos	Timmons and Co.	Bristol-Myers Squibb
Lisa Kountoupes	Ricchetti Inc.	Eli Lilly & Co.; Novartis; Pharmacia
Daniel Kracov	Patton Boggs	Hoffmann-La Roche
Craig Kramer	Johnson & Johnson	In-House
Kevin Kraushaar	Consumer Healthcare Products Assn.	In-House
Bruce Kuhlik	Covington & Burling	Consumer Healthcare Products Assn.; Merck & Co.
Jeffrey Kushan	Powell, Goldstein, Frazer & Murphy	Biotechnology Industry Organization; Genentech; Pharmaceutical Research and Manufacturers of America
Ed Kutler	Clark & Weinstock	Eli Lilly & Co.; Pharmaceutical Research and Manufacturers of America; Schering-Plough
Stephen Lacey	Olsson, Frank and Weeda, PC	Eon Laboratories; National Association of Pharmaceutical Manufacturers; Taro Pharmaceuticals
Louis LaMarca	Pfizer	In-House
David Landside	Abbott Laboratories	In-House
Jennifer Larkin	Barbour Griffith & Rogers	Bristol-Myers Squibb; GlaxoSmithKline
Dave Larson	Arent Fox Kintner Plotkin & Kahn	Aventis Pasteur; Pharmaceutical Research and Manufacturers of America
Richard Lauderbaugh	Health Policy Alternatives	Pharmaceutical Research and Manufacturers of America
Steve Lawton	Biotechnology Industry Organization	In-House
Elaine Leavenworth	Abbott Laboratories	In-House
Norman Lent	Lent Scrivner & Roth	Pfizer
Susan Lent	Akin, Gump, Strauss, Hauer & Feld	Pfizer
Norman Lent III	Lent Scrivner & Roth	Pfizer
Kathleen Lester	Patton Boggs	Bristol-Myers Squibb; Schering-Plough
Kenneth Levine	Levine & Co.	Schering-Plough
Rita Lewis	The Washington Group	Amgen; IVAX
James Lightfoot	Buchanan Ingersoll	Sidmark Laboratories
Kim Linthicum	Eli Lilly & Co.	In-House
Nick Littlefield	Foley, Hoag & Eliot; Biogen	Amgen; Biogen; Genzyme; Pharmaceutical Research and Manufacturers of America
Drew Littman	PodestaMattoon	Genentech; Genzyme; Serono Laboratories
Robert Lively	Schering-Plough	In-House



Bob Livingston	Livingston-Moffett Global	Pharmacia
Tom Loeffler	Loeffler, Jonas & Tuggey	Bristol-Myers Squibb
G. Thomas Long	Watson Pharmaceuticals	In-House
Jorge Lopez, Jr.	Akin, Gump, Strauss, Hauer & Feld	Johnson & Johnson; Pfizer
Leah Lorber	Shook, Hardy & Bacon	Eli Lilly & Co.
James Losey	Skadden, Arps, Slate, Meagher & Flom	GlaxoSmithKline
Michael Losow	Biotechnology Industry Organization	In-House
P. Vincent LoVoi	Akin, Gump, Strauss, Hauer & Feld	Pfizer
William Lucas	Pharmaceutical Research and Manufacturers of America	In-House
Ann-Marie Lynch	Pharmaceutical Research and Manufacturers of America	In-House
Karina Lynch	Williams & Jensen, PC	Abbott Laboratories; American Home Products; AstraZeneca Pharmaceuticals; Bayer Corp.; DuPont Pharmaceuticals; Genentech; Novartis; Pharmaceutical Research and Manufacturers of America
Matthew Lyons	Biotechnology Industry Organization	In-House
Jeffrey MacKinnon	Ryan, Phillips, Utrecht & MacKinnon	Pfizer
Lauren Maddox	PodestaMattoon	Genentech; Genzyme; Serono Laboratories
Mimi Mager	Heidepriem & Mager	American Home Products
Paul Magliocehetti	The PMA Group	Biogen; Generic Pharmaceutical Assn.; Pharmaceutical Research and Manufacturers of America
Karen Marangi	Patton Boggs	Bristol-Myers Squibb
Christine Maroulis	The Wexler Group	American Home Products; Immunex; IMS Health
Allen Martin	Livingston-Moffett Global	Pharmacia
Jack Martin	Parry, Romani, DeConcini & Symms	ANDRX; Aventis; Pfizer; Pharmacia; Watson Pharmaceuticals
Jose Martinez	Loeffler, Jonas & Tuggey	Bristol-Myers Squibb
Warren Maruyanna	Hogan & Hartson	Pharmaceutical Research and Manufacturers of America
G. David Mason	The Legislative Strategies Group	Amgen; Biogen; Eli Lilly & Co.; Hoffman-LaRoche; Novartis Corp.
James Massie	Alpine Group	Biotechnology Industry Organization
Jim Mathews	Clark & Weinstock	Pharmaceutical Research and Manufacturers of America
Daniel Mattoon	PodestaMattoon	Genentech; Genzyme; Serono Laboratories
Marshall Matz	Olsson, Frank and Weeda, PC	Eon Laboratories; National Association of Pharmaceutical Manufacturers; Taro Pharmaceuticals
Michael Maves	Consumer Healthcare Products Assn	In-House
Singleton McAllister	Patton Boggs	Bristol-Myers Squibb

Steve McBee	Denny Miller McBee Assn.	Cell Therapeutics
James McCarthy	Procter and Gamble	In-House
Justin McCarthy	Pfizer	In-House
John McGovern, Jr.	Higgins, McGovern & Smith	Mylan Laboratories
Mary McGrane	Genzyme	In-House
Dyan McGrath	AstraZeneca Pharmaceuticals	In-House
Michael McGregor	Williams & Jensen, PC	Genentech
Kevin McGuiness	McGuiness & Holch	Barr Laboratories
Marty McGuinness	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Lisa McHenry White	Verner, Liipfert, Bernard, McPherson & Hand	Amgen
Patrick McLain	GlaxoSmithKline	In-House
Michael McLaughlin	Winston and Strawn	Barr Laboratories
John McMackin	Williams & Jensen, PC	American Home Products
Diane McMahan	Mayer, Brown, Rowe & Maw	Pharmacia
John McMaude	Winston and Strawn	Barr Laboratories
Stephen McMillan	AstraZeneca Pharmaceuticals	In-House
Nancy McNally	Van Ness Feldman, A Professional Corp.	McKesson HBOC
Kathleen Means	Patton Boggs	Bristol-Myers Squibb
Charles Mellody	The OB-C Group	Biotechnology Industry Organization
Richard Meltzer	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
H.W. "Buddy" Menn III	Generic Pharmaceutical Assn.	In-House
Charles Merin	BKSH & Associates	Genentech
Daniel Meyer	The Duberstein Group	Pharmacia
Laurie Michel	Merck & Co.	In-House
Ed Mihalski	Eli Lilly & Co.	In-House
Denny Miller	Denny Miller McBee Assn.	Cell Therapeutics
R. Scott Miller	Procter and Gamble	In-House
Mark Mioduski	Biogen; The PMA Group	Biogen; Pharmaceutical Research and Manufacturers of America
Diane Moery	Fierce & Isakowitz	Generic Pharmaceutical Assn.
Anthony Moffett	Livingston-Moffett Global	Pharmacia
Dave Mohler	Pharmaceutical Research and Manufacturers of America	In-House
Susan Molinari	The Washington Group	Amgen; IVAX
Loren Monroe	Barbour Griffith & Rogers	Amgen; Bristol-Myers Squibb; GlaxoSmithKline
John Moore	Marwood Group	Bristol-Myers Squibb
Walter Moore	Genentech	In-House
Cynthia Moran	Pharmacia	In-House
Elizabeth Morra	PodestaMattoon	Genentech; Genzyme
Timothy Morrison	Clark & Weinstock	Eli Lilly & Co.; Pharmaceutical Research and Manufacturers of America
Phil Moseley	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly &

		Co.; Johnson & Johnson; Pfizer
Randolph Moss	Wilmer, Cutler & Pickering	American Home Products
Russell Mueller	Greenberg Traurig; HC Associates	Amgen; Genzyme; Pharmaceutical Research and Manufacturers of America
Heather Mullen	Pfizer	In-House
Rick Murphy	R B Murphy & Associates	Pharmaceutical Research Manufacturers & Associates
Sean Murphy	Mayer, Brown, Rowe & Maw	Pharmacia
James Musser	Kessler & Associates Business Services	Amgen; GlaxoSmithKline
Jeff Myers	Pharmacia	In-House
Chris Myrick	American Home Products	In-House
Martha Naismith	Johnson & Johnson	In-House
David Nelson	David Nelson & Associates	Barr Laboratories
Patricia Nelson	The OB-C Group	Biotechnology Industry Organization
Robert Neuman	Neuman and Co.	Amgen
Darryl Nirenberg	Patton Boggs	Bristol-Myers Squibb
William Nixon	Generic Pharmaceutical Assn.	In-House
Hallock Northcott	Kessler & Associates Business Services	Amgen; Novartis; Pfizer; Pharmacia
Rita Norton	Amgen	In-House
Marcia Nusgart	Nusgart Consulting	Johnson & Johnson; Mallinckrodt
Karen Nussle	BKSH & Associates	Bristol-Myers Squibb; GlaxoSmithKline
Michael O'Brien	Verner, Liipfert, Bernard, McPherson & Hand	Pharmaceutical Research and Manufacturers of America
Lawrence O'Brien III	The OB-C Group	Biotechnology Industry Organization
G. John O'Hanlon	The Washington Group	Amgen; IVAX
Joseph O'Leary	Winston and Strawn	Barr Laboratories
Joe O'Neill	Public Strategies Washington	Bristol-Myers Squibb
Teel Oliver	Merck & Co.	In-House
George Olsen	Williams & Jensen, PC	Abbott Laboratories; American Home Products; AstraZeneca Pharmaceuticals; Bayer; DuPont Pharmaceuticals; Genentech; Novartis; Pharmaceutical Research and Manufacturers of America
Scott Olsen	Pharmaceutical Research and Manufacturers of America	In-House
Jonathan Orloff	Biogen	In-House
William Owen	Asset & Equity Corp.	Theragenics
Stuart Pape	Patton Boggs	Bristol-Myers Squibb; Hoffmann-La Roche
Michael Parini	Akin, Gump, Strauss, Hauer & Feld	Pfizer
Eugene Patrone	The Washington Group	Amgen; IVAX
Doug Patton	Holland & Knight	American Home Products
Bill Paxon	Akin, Gump, Strauss, Hauer & Feld	Johnson & Johnson; Pfizer
Layna Peltier	Capitol Health Group	Abbott Laboratories; Bristol-Myers Squibb; Johnson & Johnson; Pfizer; Pharmaceutical

		Research and Manufacturers of America
Phillips Peter	Reed Smith Shaw & McClay	Abbott Laboratories
Geoffrey Peterson	Aventis Pasteur	In-House
Matthew Peterson	AstraZeneca Pharmaceuticals; Foxkiser	AstraZeneca
Michael Petty	Bennett, Turner & Coleman	Serono Holdings
James Phelps	Hyman, Phelps & McNamara	Medeva Pharmaceuticals
Mike Phillips	Biotechnology Industry Organization	In-House
William Phillips	Ryan, Phillips, Utrecht & MacKinnon	Pfizer
Neil Pickett	Eli Lilly & Co.	In-House
James Pickup	Verner, Liipfert, Bernhard, McPherson & Hand	Biovail Corp. International
Mark Planning	Ryan, Phillips, Utrecht & MacKinnon	Pfizer
Jon Plebani	Loeffler, Jonas & Tuggey	Bristol-Myers Squibb
Anthony Podesta	PodestaMattoon	Genentech; Genzyme
Franklin Polk	Kessler & Associates Business Services	Amgen; Novartis; Pfizer
Jaqui Pomfret	Pharmaceutical Research and Manufacturers of America	In-House
Donald Pongrace	Akin, Gump, Strauss, Hauer & Feld	Pfizer
John Porter	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Tim Powers	PodestaMattoon	Genentech; Genzyme; Serono Laboratories
Jessica Powley	Marwood Group	Bristol-Myers Squibb
David Quam	Powell, Goldstein, Frazer & Murphy	Biotechnology Industry Organization; Genentech; Pharmaceutical Research and Manufacturers of America
Patrick Quinn	The Accord Group	Procter & Gamble
Julie Rabinowitz	American Home Products	In-House
John Raffaelli	The Washington Group	Amgen; IVAX
Pat Raffaniello	PricewaterhouseCoopers	Schering-Plough
Lisa Raines	Genzyme	In-House
Stacy Rampy	Merck & Co.	In-House
Lee Rawls	Biotechnology Industry Organization	In-House
Tyson Redpath	Olsson, Frank and Weeda	Eon Laboratories; Taro Pharmaceuticals
Brenda Reese	Bergner Bockorny Castagnetti Hawkins & Brain	Biogen; Bristol-Myers Squibb; Genzyme; GlaxoSmithKline
Karen Regan	Verner, Liipfert, Bernard, McPherson & Hand	Amgen
Lori Reilly	Pharmaceutical Research and Manufacturers of America	In-House
Susan Relland	Washington Council Ernst & Young	Pfizer
Jeff Ricchetti	Ricchetti Inc.	Eli Lilly & Co.; Novartis; Pharmacia
Steve Ricchetti	Ricchetti Inc.	Eli Lilly & Co.; Novartis; Pharmacia

Ann Richardson Berkey	McKesson HBOC	In-House
Anthony Roda	Williams & Jensen, PC	Genentech; Pharmaceutical Research and Manufacturers of America
Edward Rogers Jr.	Barbour Griffith & Rogers	Amgen; Bristol-Myers Squibb; GlaxoSmithKline
Martin Rohling	Albers & Co.	Eli Lilly & Co.
Mark Rokala	The PMA Group	Generic Pharmaceutical Assn.; Pharmaceutical Research and Manufacturers of America
Susan Rolland	Washington Council Ernst & Young	Baxter Healthcare Corp.
Romano Romani	Parry, Romani, DeConcini & Symms	ANDRX; Aventis; Pfizer; Pharmacia; Watson Pharmaceuticals
Michael Romansky	McDermott, Will & Emery	Allergan
Patrick Ronan	Biotechnology Industry Organization	In-House
Burt Rosen	Novartis	In-House
Andrew Rosenberg	Patton Boggs	Bristol-Myers Squibb; Hoffmann-La Roche
Thomas Rosenkoetter	Williams & Jensen, PC	Bayer Corp.; Novartis; Pharmaceutical Research and Manufacturers of America
Lisa Ross	Ogilvy Public Relations Worldwide	Merck & Co.
Brad Rossin	Baxter Healthcare Corp.	In-House
Alan Roth	Lent Scrivner & Roth	Pfizer
Nicole Rowe	The Washington Group	Amgen
Bob Rozen	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Peter Rubin	Pharmaceutical Research and Manufacturers of America	In-House
David Rudd	Hooper Owen & Winburn	Pfizer
Nicholas Ruggieri	Serono Laboratories	In-House
John Ryan	Bristol-Myers Squibb	In-House
Thomas Ryan	Ryan, Phillips, Utrecht & MacKinnon	Pfizer
Shannon Salmon	Johnson & Johnson	In-House
Marc Samuels	Marc Blaine Samuels	American Home Products
Timothy Sanders	The PMA Group	Biogen; Generic Pharmaceutical Assn.; Pharmaceutical Research and Manufacturers of America
Edward Sargent	Merck & Co.	In-House
Albert Saunders	Saunders Consulting	Pharmaceutical Research and Manufacturers of America
Tonya Saunders	The Washington Group	Amgen; IVAX
Peter Scher	Mayer, Brown, Rowe & Maw	Pharmacia
James Schlicht	AstraZeneca Pharmaceuticals	In-House
Mark Schnabel	The Washington Group	Amgen; IVAX
Andrew Schneider	PodestaMattoon	Genentech
Melissa Schulman	Bergner Bockorny Castagnetti Hawkins & Brain; Biogen	Biogen; Bristol-Myers Squibb; Genzyme; GlaxoSmithKline
William Schultz	Zuckerman Spaeder	ANDRX; Barr Laboratories; Serono Laboratories
William Schuyler	GlaxoSmithKline	In-House

Victor Schwartz	Crowell & Moring; Shook, Hardy & Bacon	Eli Lilly & Co.
Paul Scolese	Akin, Gump, Strauss, Hauer & Feld	Pfizer
Michael Scrivner	Lent Scrivner & Roth	Pfizer
Wynn Segall	Akin, Gump, Strauss, Hauer & Feld	American Home Products
Cynthia Sensibaugh	Abbott Laboratories	In-House
Dennis Shea	BKSH & Associates	Bristol-Myers Squibb
Andrew Shoyer	Powell, Goldstein, Frazer & Murphy	Pharmaceutical Research and Manufacturers of America
Julie Shroyer	Wheat & Associates	GlaxoSmithKline
Kathleen Siedlecki	Fleishman-Hillard	Abbott Laboratories
Suzanne Simala	Eli Lilly & Co.	In-House
Edgar Sims	Long Aldridge & Norman	Biotechnology Industry Organization
Stephen Sims	Stephen F. Sims & Associates	Barr Laboratories
Barney Skladany	Akin, Gump, Strauss, Hauer & Feld	Johnson & Johnson; Serono Laboratories
Linda Skladany	Parry, Romani, DeConcini & Symms	ANDRX; Aventis; Pfizer; Pharmacia; Watson Pharmaceuticals
Scott Slaughter	Multinational Business Services	Aventis
Clyde Slease III	Doepken Keevican & Weiss	Mylan Laboratories
Cynthia Smith	Merck & Co.	In-House
Gare Smith	Foley, Hoag & Eliot	Genzyme
Larry Smith	The Legislative Strategies Group	Amgen; Biogen; Eli Lilly & Co.; Hoffman-LaRoche; Novartis
Linden Smith	KPMG	Biotechnology Industry Organization
Mark Smith	Shaw Pittman	Biotechnology Industry Organization
Wendy Smith Fuss	Alpine Group	Pharmacia
Margaret Smith Hemmer	Bergner Bockorny Castagnetti Hawkins & Brain	Biogen; Bristol-Myers Squibb; Genzyme; GlaxoSmithKline
Dale Snape	The Wexler Group	Hoffmann LaRoche; Immunex; American Home Products
Paul Snyder	Public Strategies Washington	Bristol-Myers Squibb
Ian Spatz	Merck & Co.	In-House
Jonathan Spear	Baxter Healthcare Corp.	In-House
James Spears	Ropes & Gray	Aventis Pharmaceuticals
Daniel Spiegel	Akin, Gump, Strauss, Hauer & Feld	American Home Products; Serono Laboratories
Harry Spordis	Kessler & Associates Business Services; The Washington Group	Amgen; Pharmacia; IVAX
Diedre Stach	Clark & Weinstock	Eli Lilly & Co.; Pharmaceutical Research and Manufacturers of America; Schering-Plough
Donna Steele-Flynn	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Deborah Steelman	Eli Lilly & Co.; Steelman Health Strategies	In House; Bristol-Myers Squibb; Johnson & Johnson; Pfizer; Pharmaceutical Research and Manufacturers of America
Dana Stewart	The PMA Group	Biogen
Shelley Stewart	Pharmaceutical Research and	In-House

	Manufacturers of America	
John Stinson	Forscey & Stinson	Barr Laboratories
J. Vander Stoep	Washington 2 Advocates	Immunex
Ryan Stroschein	Olsson, Frank and Weeda	Eon Laboratories; Taro Pharmaceuticals
Sandi Stuart	Clark & Weinstock	Pharmaceutical Research and Manufacturers of America; Schering-Plough
Scott Styles	Bergner Bockorny Castagnetti Hawkins & Brain	Biogen; Bristol-Myers Squibb; Genzyme; GlaxoSmithKline
Richard Sullivan	The Washington Group	IVAX
Patricia Sunseri	Mylan Laboratories	In-House
Thomas Susman	Ropes & Gray	Aventis Pharmaceuticals
Andrew Swire	Amgen	In-House
Steve Symms	Parry, Romani, DeConcini & Symms	ANDRX; Aventis; Pfizer; Pharmacia; Watson Pharmaceuticals
Linda Tarplin	The OB-C Group	Biotechnology Industry Organization
Richard Tarplin	Timmons and Co.	Bristol-Myers Squibb
Jeffrey Tassej	Williams & Jensen, PC	AstraZeneca Pharmaceuticals; Novartis
Nancy Taylor	Greenberg Traurig	Genzyme
Tracy Taylor	Williams & Jensen, PC	Pharmaceutical Research and Manufacturers of America
Wendy Taylor	Biotechnology Industry Organization	In-House
Peter Teeley	Amgen	In-House
Henry Terhune	Akin, Gump, Strauss, Hauer & Feld	Pfizer
Judi Teske	Amgen	In-House
Richard Thompson	Bristol-Myers Squibb	In-House
Craig Thorn	DTB Associates; Powell, Goldstein, Frazer & Murphy	Alpharma USPD; Biotechnology Industry Organization
Steve Tilton	Health Policy Analysts	Schering-Plough
William Timmons, Jr.	Timmons and Co.	Bristol-Myers Squibb
Francis Tirrell	Abbott Laboratories	In-House
Darla Tomes	Kessler & Associates Business Services	Pharmacia
Michael Tongour	Tongour Simpson Holsclaw Green	Aventis Pharmaceuticals; Pharmaceutical Research and Manufacturers of America
Jim Tozzi	Multinational Business Services	Aventis
Brad Traverse	US Strategies	IVAX
Frankie Trull	Policy Directions	Amgen; Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Merck & Co.; Pharmaceutical Research and Manufacturers of America
Timothy Trysla	Greenberg Traurig	Genzyme
Arthur Tsien	Olsson, Frank and Weeda, PC	National Association of Pharmaceutical Manufacturers
Robert Tucker	William J. Harte, Ltd.	Amgen
James Tucker, Jr.	Akin, Gump, Strauss, Hauer & Feld	Johnson & Johnson
Sam Turner	Bennett, Turner & Coleman	Abbott Laboratories; AstraZeneca LP; Bristol- Myers Squibb; Eli Lilly & Co.; Johnson &

		Johnson/Ortho Biotech; Novartis; Pfizer
Phil Ufholz	Biotechnology Industry Organization	In-House
Anne Urban	Clark & Weinstock	Eli Lilly & Co.; Pharmaceutical Research and Manufacturers of America
Timothy Urban	Washington Council Ernst & Young	Aventis; Baxter Healthcare Corp.; Eli Lilly & Co.; Johnson & Johnson; Pfizer
Juliane Van Egmond	Bayer	In-House
Matthew Van Hook	Pharmaceutical Research and Manufacturers of America	In-House
Joseph Vasapoli	Ryan, Phillips, Utrecht & MacKinnon	Pfizer
Jay Velasquez	Public Strategies	Aventis Pharmaceuticals
Ann Morgan Vickery	Hogan & Hartson	Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Pharmaceutical Research and Manufacturers of America
Bill Viney	Broydrick & Associates	Abbott Laboratories; Barr Laboratories
Beth Viola	Holland & Knight	American Home Products
Frank Vlossak	Williams & Jensen, PC	AstraZeneca Pharmaceuticals; Genentech; Novartis; Pharmaceutical Research and Manufacturers of America
Heidi Wagner	Genentech	In-House
John Waits	Winston and Strawn	Barr Laboratories
Daniel Waldmann	Public Policy Partners	Johnson & Johnson
Robert Walker	The Wexler Group	Immunex; American Home Products
Benjamin Wallfisch	Patton Boggs	Bristol-Myers Squibb
Sarah Walsh	GlaxoSmithKline	In-House
Jeffrey Walter	The Washington Group	IVAX
William Walters	Canfield & Associates; Pharmaceutical Research and Manufacturers of America	Pharmaceutical Research and Manufacturers of America
David Warr	Bristol-Myers Squibb	In-House
Jennifer Wayman	Ogilvy Public Relations Worldwide	Merck & Co.
Vin Weber	Clark & Weinstock	Eli Lilly & Co.; Pharmaceutical Research and Manufacturers of America; Schering-Plough
David Weeda	Olsson, Frank and Weeda, PC	National Association of Pharmaceutical Manufacturers
Jeffrey Weekly	Public Policy Partners	Johnson & Johnson
Michael Werner	Biotechnology Industry Organization	In-House
Michael Wessel	Downey McGrath Group	Merck & Co.
Fowler West	The Washington Group	Amgen; IVAX
Anne Wexler	The Wexler Group	Immunex
Mary Whalen	Williams & Jensen	Genentech
Alan Wheat	Wheat & Associates	GlaxoSmithKline
Richard White	Alpine Group	DuPont Pharmaceuticals; Pharmacia
Sam White	Alpine Group	Biotechnology Industry Organization
Jamie Whitehead	Marwood Group	Bristol-Myers Squibb



David Whitestone	Holland & Knight	American Home Products
Marcy Wilder	Hogan & Hartson	Biotechnology Industry Organization
Richard Wilder	Powell, Goldstein, Frazer & Murphy	Biotechnology Industry Organization; Pharmaceutical Research and Manufacturers of America
Cynthia Wilkinson	Twenty-First Century Group	Schering-Plough
J.D. Williams	Williams & Jensen, PC	Genentech
Kimberly Williams	GlaxoSmithKline	In-House
Patrick Williams	Higgins, McGovern & Smith	Amgen
Tony Williams	Washington 2 Advocates	Immunex
JoAnn Willis	Patton Boggs	Bristol-Myers Squibb; Hoffmann-La Roche
S. Bruce Wilson	Akin, Gump, Strauss, Hauer & Feld	American Home Products; Serono Laboratories
John Winburn	Hooper Owen & Winburn	Pfizer
Sandra Windsor Mathiesen	Denny Miller McBee Assn.	Cell Therapeutics
Steven Wright	Holland & Knight	American Home Products
Elizabeth York	GlaxoSmithKline	In-House
Eric Zimmerman	McDermott, Will & Emery	Allergan
Donald Zowader	Aventis Pharma AG	In-House

Source: Public Citizen analysis of Lobby Disclosure reports filed with the Secretary of the Senate and Clerk of the House pursuant to the Lobby Disclosure Act of 1995.

## Endnotes

---

<sup>1</sup> Public Citizen, “Patently Offensive: Congress Set to Extend Monopoly Patents for Cipro and Other Drugs,” November 2001.

[http://www.citizen.org/congress/reform/drug\\_patents/pediatric/articles.cfm?ID=6435](http://www.citizen.org/congress/reform/drug_patents/pediatric/articles.cfm?ID=6435)

<sup>2</sup> PoliticalMoneyLine, “Lobbying Expenditures Dropped In First Six Months of 2001,” press release, April 22, 2002. Data for the full year (2001) is not yet available, but PoliticalMoneyLine (politicalmoneyline.com) reported that total Washington, D.C. lobbying expenditures for the first six months of 2001 were \$790 million, which was a 5 percent decrease from the total of \$831 million for the last six months of 2000.

<sup>3</sup> Public Citizen analysis of lobby disclosure reports filed with the Secretary of the Senate and Clerk of the House pursuant to the Lobby Disclosure Act of 1995.

<sup>4</sup> Public Citizen, “The Other Drug War: Big Pharma’s 625 Washington Lobbyists,” July 2001.

[http://www.citizen.org/congress/campaign/special\\_interest/articles.cfm?ID=6537](http://www.citizen.org/congress/campaign/special_interest/articles.cfm?ID=6537)

<sup>5</sup> PoliticalMoneyLine reported in its April 22, 2002 press release that the health care industry remained the top spending industry and the pharmaceutical manufacturers were the largest sector, spending almost \$38 million in the first six months of 2001.

<sup>6</sup> Dan Morgan, “A Revolving Door Where Rules Don’t Apply,” *The Washington Post*, July 21, 1997, page A6.

<sup>7</sup> Public Citizen analysis of lobby disclosure reports filed with the Secretary of the Senate and Clerk of the House pursuant to the Lobby Disclosure Act of 1995.

<sup>8</sup> Pharmaceutical Research and Manufacturers of America (PhRMA), “Pediatric Incentive for Pharmaceutical Products, November 1997 to February 2001.” “Because of the small market for pediatric formulations, a pharmaceutical manufacturer has no incentive to invest resources in public trials,” according to PhRMA.

<sup>9</sup> Christopher-Paul Milne, “The Pediatric Studies Incentive: Equal Medicines For All,” Tufts Center for the Study of Drug Development, April 2001.

<sup>10</sup> Public Citizen, “Patently Offensive: Congress Set to Extend Monopoly Patents for Cipro and Other Drugs,” November 2001. Based on a formula used by the U.S. Food and Drug Administration, Public Citizen calculated that a six-month patent extension was worth \$1.4 billion in added sales for Prilosec, and \$1.3 billion in added sales for Lipitor.

<sup>11</sup> U.S. Food and Drug Administration (FDA), “The Pediatric Exclusivity Provision: Status Report to Congress,” January 2001.

<sup>12</sup> Statement of Congressman Henry A. Waxman (D-Calif.), at the House Energy and Commerce Committee markup on pediatric exclusivity, October 4, 2001.

---

<sup>13</sup> *Congressional Quarterly Monitor*, House Subcommittee on Health, Committee on Energy and Commerce, votes on H.R. 2887, October 4, 2001.

<sup>14</sup> *Ibid.* Health Subcommittee Democrats who voted consistently against the pro-consumer amendments were Reps. Anna Eshoo of California, Ted Strickland of Ohio, Edolphus Towns of New York, and Albert Wynn of Maryland.

<sup>15</sup> Public Citizen interview with House staff member, September 17, 2001.

<sup>16</sup> Public Citizen interview with AAP lobbyist Elaine (Holland) Vining, October 31, 2001. “For 40 years we’ve tried to get these tests,” Vining explained, “and now we have a bill that’s working for kids. Nobody could guarantee us that paying the companies two times the cost of the studies would get us the studies ... Is there a better way so consumers pay less? Possibly. Will we lose something that way? Maybe.”

<sup>17</sup> Public Citizen, “Patently Offensive: Congress Set to Extend Monopoly Patents for Cipro and Other Drugs,” November 2001. PhRMA gave \$70,000 to the Children’s Health Coalition in the summer of 2001. The Children’s Health Coalition was chaired by Audrey Spolarich, who was a paid lobbyist for drugmaker Schering-Plough in 2000.

<sup>18</sup> Public Citizen interview with House staff member, October 29, 2001.

<sup>19</sup> Public Citizen analysis of Lobby Disclosure reports filed with the Secretary of the Senate and Clerk of the House pursuant to the Lobby Disclosure Act of 1995.

<sup>20</sup> *Ibid.*

<sup>21</sup> *Ibid.*

<sup>22</sup> Public Citizen interview with Senate staff member on September 17, 2001.

<sup>23</sup> Public Citizen analysis of Lobby Disclosure reports filed with the Secretary of the Senate and Clerk of the House pursuant to the Lobby Disclosure Act of 1995 and Public Citizen interview with Senate staff member on September 17, 2001.

<sup>24</sup> Public Citizen analysis of Lobby Disclosure reports filed with the Secretary of the Senate and Clerk of the House pursuant to the Lobby Disclosure Act of 1995.

<sup>25</sup> National Institute for Health Care Management, “Prescription Drugs and Intellectual Property Protection,” August 2000. The generic drug market share declined from 10.4 percent of dollar sales in 1993 to 8.6 percent in 1998.

<sup>26</sup> Judy Sarasohn, “Ex-McCain Aide’s New Drug Regimen,” *The Washington Post*, June 6, 2002, pg A29.

<sup>27</sup> *Ibid.*